melatonin has been researched along with Blood Pressure, High in 173 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral melatonin is a potential alternative treatment for hypertension and nocturnal hypertension." | 9.22 | Controlled-release oral melatonin supplementation for hypertension and nocturnal hypertension: A systematic review and meta-analysis. ( Chung, VC; Lee, EK; Lee, VW; Poon, P; Wong, SY; Yu, CP, 2022) |
| "The incidence of dysmetabolic factors in 100 elderly patients with hypertension stage II and the role of melatoninproducing function of epiphysis (pineal gland) in the development of these disorders were studied." | 9.16 | [Metabolic disorders in elderly patients with hypertension and their correction with melatonin]. ( Antoniuk-Shcheglova, IA; Bondarenko, EV; Shatilo, VB, 2012) |
| "Study of 2 randomized groups of patients with coronary heart disease, stable exertional angina combined with arterial hypertension, receiving traditional treatment and combined therapy with inclusion of melatonin, was performed." | 9.13 | [Melatonin in combined therapy of patients with stable angina and arterial hypertension]. ( Logvinenko, SI; Shcherban', EA; Zaslavskaia, RM, 2008) |
| "Thirty-eight treated hypertensive patients (22 males, mean age 64+/-11 years) with confirmed nocturnal hypertension (mean nighttime systolic BP >125 mm Hg), according to repeated 24-hour ambulatory blood pressure monitoring (ABPM), were randomized in a double-blind fashion to receive either controlled release (CR)-melatonin 2 mg or placebo 2 hours before bedtime for 4 weeks." | 9.12 | Melatonin reduces night blood pressure in patients with nocturnal hypertension. ( Grossman, E; Kamari, Y; Laudon, M; Peleg, E; Sharabi, Y; Shen-Orr, Z; Yalcin, R; Zengil, H; Zisapel, N, 2006) |
| "Twenty-four hour noninvasive blood pressure monitoring performed before and during melatonin cure is crucial by considering benefits and dangers of this treatment begun in purpose to modify impaired pattern of blood pressure in patients with coronary artery disease." | 9.12 | [The influence of melatonin supplementation on circadian pattern of blood pressure in patients with coronary artery disease--preliminary report]. ( Krzeminska-Pakuła, M; Kurpesa, M; Rechciński, T; Trzos, E, 2006) |
| "To study effects of monotherapy with melatonin and combination melatonin + aceten on circadian pattern of hemodynamics in patients with essential hypertension stage II." | 9.09 | [Effects of melatonin alone and in combination with aceten on chronostructure of diurnal hemodynamic rhythms in patients with hypertension stage II]. ( Akhmetov, KZh; Komarov, FI; Shakirova, AN; Teĭblium, MM; Zaslavskaia, RM, 1999) |
| "The chronopharmacodynamics of angiotension-converting enzyme (ACE) inhibitors, such as ramipril (R), enalapril (E), acetene (A), caposide-50 (C-50) and the effect of the epiphyseal neurohormone melatonin used alone and in combination with cozaar (Co) and cintome (Ci) in the randomized groups including 124 patients with arterial hypertension (AH)." | 9.09 | [Time-dependent effects of antihypertensive agents and chronocorrecting action of melatonin in patients with arterial hypertension]. ( Biiasilov, N; Komarov, FI; Makarova, LA; Narmanova, OZh; Shakirova, AN; Zaslavskaia, RM, 2000) |
| "Monotherapy with caposide-50 (C-50) was compared to combined therapy C-50 + melatonin in 22 patients with essential hypertension stage II (mean age 60 years)." | 9.09 | [Capozide-50 alone and in combination with melatonin in therapy of hypertension]. ( Akhmetov, KZh; Biiasilov, NS; Teĭblium, MM; Zaslavskaia, RM, 2000) |
| " In this study the effect of ten weeks treatment with the beta-adrenoreceptor (beta-AR) blockers propranolol and ridazolol on melatonin synthesis and on sleep quality was examined in 42 patients suffering from essential hypertension." | 9.07 | Influence of chronic beta-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension. ( Demisch, L; Rommel, T, 1994) |
| "Here, we review the known relations between hypertension and obesity to inflammation and postulate the endogenous protective effect of melatonin and its potential as a therapeutic agent." | 8.98 | Anti-Inflammatory Effects of Melatonin in Obesity and Hypertension. ( Diez, ER; Ferder, L; Manucha, W; Prado, NJ, 2018) |
| "Melatonin secreted by the pineal gland plays an important role in the regulation of blood pressure (BP) and its administration reduces hypertension both in animals and humans." | 8.89 | Experimental models of melatonin-deficient hypertension. ( Paulis, L; Pechanova, O; Reiter, RJ; Simko, F, 2013) |
| "A test of the relative merits of timed melatonin for the treatment of cardiac ischemia as well as hypertension refractory to other drugs is documented against the background of earlier chronobiological studies on blood pressure (BP), disease risks, circadian hyper-amplitude-tension and melatonin effects broadly." | 8.82 | Melatonin, refractory hypertension, myocardial ischemia and other challenges in nightly blood pressure lowering. ( Bakken, EE; Cornélissen, G; Dilmagambetova, GS; Halberg, F; Ikonomov, O; Lilitsa, GV; Otsuka, K; Perfetto, F; Schwartzkopff, O; Singh, RB; Stoynev, A; Tarquini, R; Zaslavskaya, RM, 2004) |
| "The aim: Of the study was to investigate the effect of melatonin on the serum levels of ghrelin in patients with hypertension combined with osteoarthritis in order to identify them as informative and reliable markers of early diagnosis of progression of these comorbid diseases." | 8.02 | MELATONIN AND GRHELIN AS "EARLY" PROGNOSIS MARKERS OF PROGRESSION OF ARTERIAL HYPERTENSION AND OSTEOARTHRITIS IN THE CASE OF THEIR COMORBIDITY. ( Ilashchuk, TO; Navchuk, IV; Sobko, DI, 2021) |
| "The objective was to investigate the effects of melatonin and exercise on insulin resistance (IR), hypertension and fatigue syndrome in a rat model of type 2 diabetes mellitus (T2DM)." | 7.85 | Melatonin supplementation plus exercise behavior ameliorate insulin resistance, hypertension and fatigue in a rat model of type 2 diabetes mellitus. ( Go, HK; Kim, DH; Kim, MJ; Kwon, HS; Oak, MH; Rahman, MM, 2017) |
| "Hypertension can originate from early-life insults, whereas maternal melatonin therapy can be protective in a variety of models of programmed hypertension." | 7.85 | Maternal melatonin or agomelatine therapy prevents programmed hypertension in male offspring of mother exposed to continuous light. ( Chan, JYH; Hsu, CN; Lee, CT; Lin, YJ; Tain, YL, 2017) |
| "Exposure of rats to continuous light attenuates melatonin production and results in hypertension development." | 7.80 | Hypertension and cardiovascular remodelling in rats exposed to continuous light: protection by ACE-inhibition and melatonin. ( Adamcova, M; Celec, P; Gvozdjakova, A; Kamodyova, N; Krajcirovicova, K; Kucharska, J; Paulis, L; Pechanova, O; Repova Bednarova, K; Simko, F; Zorad, S, 2014) |
| "Chronic continuous light exposure leads to melatonin deficiency along with complex neurohumoral activation resulting in hypertension development in rats." | 7.79 | Effect of captopril and melatonin on fibrotic rebuilding of the aorta in 24 hour light-induced hypertension. ( Adamcová, M; Aziriová, S; Hrenák, J; Krajčírovičová, K; Paulis, L; Repová-Bednárová, K; Simko, F, 2013) |
| "The study included 2 groups of patients with arterial hypertension and coronary heart disease treated by traditional therapy or its combination with melatonin." | 7.77 | [Significance of correlation between weather factors and hemodynamic parameters in patients with arterial hypertension and coronary heart desease receiving traditional treatment and combined therapy with melatonin]. ( , 2011) |
| "We examined the association between first morning urine melatonin levels and the risk of developing hypertension among 554 young women without baseline hypertension who were followed for 8 years." | 7.76 | Urinary melatonin and risk of incident hypertension among young women. ( Curhan, GC; Forman, JP; Schernhammer, ES, 2010) |
| " Several groups have reported that melatonin produces a significant decrease in blood pressure in mammals and that pinealectomy in rats causes hypertension." | 7.75 | Melatonin reduces blood pressure in rats with stress-induced hypertension via GABAA receptors. ( Kang, YM; Li, HL; Xu, HY; Yu, L; Zhao, H, 2009) |
| "Oxidative stress and melatonin (the pineal hormone) are involved in the pathogenesis of aging and aging-related diseases, including essential arterial hypertension." | 7.74 | [Time dependent effect of melatonin administration on lipid peroxidation, superoxide dismutase activity and melatonin concentration in the elderly patients with essential arterial hypertension]. ( Czuczejko, J; Kedziora, J; Kedziora-Kornatowska, K; Kornatowski, T; Motyl, J; Pawluk, H; Szewczyk-Golec, K; van Marke de Lumen, K, 2008) |
| "The purpose of the study was to investigate effects of melatonin (MEL) on exploration and anxiety in normotensive Sprague-Dawley (SD) and hypertensive TGR(mREN2)27 (TGR) rats with high activity of renin-angiotensin system." | 7.74 | Effect of melatonin on exploration and anxiety in normotensive and hypertensive rats with high activity of renin-angiotensin system. ( Krsková, L; Vrabcová, M; Zeman, M, 2007) |
| "Melatonin secretion decreased in fructose fed rats that developed hypertension." | 7.74 | The role of melatonin in the pathogenesis of hypertension in rats with metabolic syndrome. ( Grossman, E; Leibowitz, A; Peleg, E; Shabtai, Z; Shamiss, A; Sharabi, Y, 2008) |
| "What is the effect of melatonin on jet lag syndrome? Jet lag desynchronizes the internal sleep-wakefulness cycle with the environmental light/dark cycle." | 7.72 | Melatonin and jet lag syndrome: experimental model and clinical implications. ( Oxenkrug, GF; Requintina, PJ, 2003) |
| ") was compared to that of Cozaar combination with melatonin (3 mg before sleep) in 21 patients with hypertension stage II (mean age 62 years)." | 7.70 | [Comparative study of the effectiveness of Cozaar monotherapy and Cozaar and melatonin combined therapy in aged patients with hypertension]. ( Goncharov, LF; Goncharova, ZF; Komarov, FI; Makarova, LA; Zaslavskaia, RM, 1998) |
| " One group received moxonidine, 40 mg, alone in the morning, the other had moxonidine in the same dose in combination with melatonin, 3 mg, overnight." | 6.69 | [Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hypertension]. ( Akhmetov, KZh; Komarov, FI; Shakirova, AN; Teĭblium, MM; Zaslavskaia, RM, 2000) |
| "Melatonin plays a crucial role in major pathological processes associated with heart failure including ischemic injury, oxidative stress, apoptosis, and cardiac remodeling." | 6.58 | Melatonin in Heart Failure: A Promising Therapeutic Strategy? ( Maarman, GJ; Nduhirabandi, F, 2018) |
| "Hypertension affects target organs in different ways and cellular energy metabolism is frequently involved due to mitochondrial alterations that include a rise in reactive oxygen species production and an ATP synthesis decrease." | 6.55 | Melatonin, mitochondria and hypertension. ( Amaral, FG; Baltatu, OC; Campos, LA; Cipolla-Neto, J, 2017) |
| "Melatonin is an endogenously produced indoleamine and secreted by the pineal gland." | 6.50 | Transcriptional regulation of programmed hypertension by melatonin: an epigenetic perspective. ( Chan, JY; Huang, LT; Tain, YL, 2014) |
| "Melatonin is a key endogenous hypotensive factor." | 6.50 | [Melatonin and arterial hypertension: from understanding pathogenesis to therapeutic modalities]. ( Pal'man, AD; Rapoport, SI, 2014) |
| " The chronic administration of melatonin to individuals with hypertension induces a measurable drop in night time systolic and diastolic blood pressure." | 6.45 | The circadian melatonin rhythm and its modulation: possible impact on hypertension. ( Korkmaz, A; Reiter, RJ; Tan, DX, 2009) |
| " Based on these data, we conducted an open-label randomized study, first, to evaluate the endothelial damage and vascular stiffness in hypertense patients; second, to test the effect of supplementation with a physiological antioxidant (melatonin 1 mg/day for 1 year) in patients with essential hypertension vs." | 5.51 | Essential Hypertension and Oxidative Stress: Novel Future Perspectives. ( Bonomini, F; Favero, G; Franco, C; Rezzani, R; Sciatti, E; Vizzardi, E, 2022) |
| " We examined whether maternal melatonin therapy can prevent maternal high-fructose combined with post-weaning high-salt diet-induced programmed hypertension in adult offspring." | 5.48 | Maternal Melatonin Therapy Attenuated Maternal High-Fructose Combined with Post-Weaning High-Salt Diets-Induced Hypertension in Adult Male Rat Offspring. ( Chan, JYH; Lee, WC; Leu, S; Tain, YL; Wu, KLH, 2018) |
| "Treatment with melatonin eliminated the deleterious effect of HSD in the kidneys of Dahl salt-sensitive rats." | 5.43 | Melatonin prevents kidney injury in a high salt diet-induced hypertension model by decreasing oxidative stress. ( Barshack, I; Grossman, E; Leibowitz, A; Shemesh, C; Volkov, A; Voloshin, K, 2016) |
| "Melatonin was administered in drinking water (0." | 5.43 | Postnatal dexamethasone-induced programmed hypertension is related to the regulation of melatonin and its receptors. ( Chang, HY; Tain, YL, 2016) |
| " Chronic administration of L-NAME induced hypertension without a change in HR." | 5.43 | Effect of ivabradine, captopril and melatonin on the behaviour of rats in L-nitro-arginine methyl ester-induced hypertension. ( Adamcova, M; Aziriova, S; Baka, T; Hodosy, J; Krajcirovicova, K; Mojto, V; Paulis, L; Repova, K; Simko, F; Slavkovsky, P; Zorad, S, 2016) |
| "Melatonin was reported to prevent hypertension development." | 5.40 | Melatonin prevents maternal fructose intake-induced programmed hypertension in the offspring: roles of nitric oxide and arachidonic acid metabolites. ( Chan, JY; Lee, WC; Leu, S; Tain, YL; Wu, KL, 2014) |
| "Melatonin was administered in drinking water at the dose of 0." | 5.40 | Melatonin prevents neonatal dexamethasone induced programmed hypertension: histone deacetylase inhibition. ( Chien, SJ; Huang, LT; Kuo, HC; Lin, IC; Tain, YL; Wu, TH, 2014) |
| "Melatonin treatment significantly mitigated the increased expression of NADPH oxidase, pro-inflammatory mediators, and adhesion molecules." | 5.39 | Melatonin ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in rats with chronic intermittent hypoxia. ( Fung, ML; Hung, MW; Kravtsov, GM; Lau, CF; Poon, AM; Tipoe, GL, 2013) |
| "Chronic L-NAME treatment induced hypertension, elevated the oxidative load and inhibited NOS activity." | 5.36 | Melatonin interactions with blood pressure and vascular function during L-NAME-induced hypertension. ( Barta, A; Celec, P; Gardlik, R; Kunes, J; Paulis, L; Pechanova, O; Simko, F; Zicha, J, 2010) |
| "Melatonin-treated rats received 0." | 5.36 | Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats. ( Huang, LT; Lau, YT; Lin, CY; Lin, IC; Tain, YL, 2010) |
| "Melatonin plays a role in blood pressure (BP) control." | 5.35 | Effect of L-NAME-induced hypertension on melatonin receptors and melatonin levels in the pineal gland and the peripheral organs of rats. ( Benova, M; Herichova, I; Krajcirovicova, K; Paulis, L; Simko, F; Stebelova, K; Zeman, M, 2009) |
| "Melatonin treatment of IH-exposed animals decreased blood pressure, blood glucose, and ROS and nitrite/nitrate levels, and increased vasodilation and capillary perfusion." | 5.35 | Melatonin reduces microvascular damage and insulin resistance in hamsters due to chronic intermittent hypoxia. ( Bertuglia, S; Reiter, RJ, 2009) |
| "Essential hypertension is a complex multifactorial disorder with epigenetic and environmental factors contributing to its prevalence." | 5.33 | Essential hypertension seems to result from melatonin-induced epigenetic modifications in area postrema. ( Irmak, MK; Sizlan, A, 2006) |
| "Melatonin was administered as an antioxidant." | 5.32 | Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. ( Nava, M; Quiroz, Y; Rodriguez-Iturbe, B; Vaziri, N, 2003) |
| "In contrast with studies in other populations, this preliminary study showed that nighttime dosing of continuous-release melatonin had no significant effect on nocturnal blood pressure in African Americans with essential hypertension when compared to placebo." | 5.30 | Nighttime administration of high-dose, sustained-release melatonin does not decrease nocturnal blood pressure in African-American patients: Results from a preliminary randomized, crossover trial. ( Abramson, JL; Bliwise, DL; Bruckman, AM; Chapman, AB; Cotsonis, GA; Johnson, SA; Rahbari-Oskoui, FF, 2019) |
| "Oral melatonin is a potential alternative treatment for hypertension and nocturnal hypertension." | 5.22 | Controlled-release oral melatonin supplementation for hypertension and nocturnal hypertension: A systematic review and meta-analysis. ( Chung, VC; Lee, EK; Lee, VW; Poon, P; Wong, SY; Yu, CP, 2022) |
| " This review article aimed to present the role of melatonin in this direction, by providing an overview of melatonin's physiology followed by its effect as a therapeutic agent in arterial hypertension and T2DM." | 5.22 | The Role of Melatonin in Chronic Kidney Disease and Its Associated Risk Factors: A New Tool in Our Arsenal? ( Kalaitzidis, RG; Theofilis, P; Vordoni, A, 2022) |
| "The incidence of dysmetabolic factors in 100 elderly patients with hypertension stage II and the role of melatoninproducing function of epiphysis (pineal gland) in the development of these disorders were studied." | 5.16 | [Metabolic disorders in elderly patients with hypertension and their correction with melatonin]. ( Antoniuk-Shcheglova, IA; Bondarenko, EV; Shatilo, VB, 2012) |
| "gov, identifier: NCT00238108; trial name: Melatonin Supplements for Improving Sleep in Individuals with Hypertension; URL: http://www." | 5.16 | Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. ( Garcia, JI; Kelly, EE; Malhotra, A; Marks, J; Morris, CJ; Scheer, FA; Shea, SA; Smales, C, 2012) |
| "The aim of the work was to assess effectiveness of melatonin monotherapy (MT) and combined treatment (CT) in aged patients with arterial hypertension (AH) and coronary heart disease (CHD)." | 5.14 | [Melatonin in the combined treatment of cardiovascular diseases]. ( Lilitsa, GV; Logvinenko, SI; Shcherban', EA; Zaslavskaia, RM, 2010) |
| "Study of 2 randomized groups of patients with coronary heart disease, stable exertional angina combined with arterial hypertension, receiving traditional treatment and combined therapy with inclusion of melatonin, was performed." | 5.13 | [Melatonin in combined therapy of patients with stable angina and arterial hypertension]. ( Logvinenko, SI; Shcherban', EA; Zaslavskaia, RM, 2008) |
| "Thirty-eight treated hypertensive patients (22 males, mean age 64+/-11 years) with confirmed nocturnal hypertension (mean nighttime systolic BP >125 mm Hg), according to repeated 24-hour ambulatory blood pressure monitoring (ABPM), were randomized in a double-blind fashion to receive either controlled release (CR)-melatonin 2 mg or placebo 2 hours before bedtime for 4 weeks." | 5.12 | Melatonin reduces night blood pressure in patients with nocturnal hypertension. ( Grossman, E; Kamari, Y; Laudon, M; Peleg, E; Sharabi, Y; Shen-Orr, Z; Yalcin, R; Zengil, H; Zisapel, N, 2006) |
| "Twenty-four hour noninvasive blood pressure monitoring performed before and during melatonin cure is crucial by considering benefits and dangers of this treatment begun in purpose to modify impaired pattern of blood pressure in patients with coronary artery disease." | 5.12 | [The influence of melatonin supplementation on circadian pattern of blood pressure in patients with coronary artery disease--preliminary report]. ( Krzeminska-Pakuła, M; Kurpesa, M; Rechciński, T; Trzos, E, 2006) |
| "To study the changes in macrophage inducible nitric oxide synthase (iNOS) activity, plasma levels of nitrite, lipid peroxidation (LPO) and melatonin in human essential hypertension before and 6 months after 4 mg/day lacidipine treatment." | 5.11 | Changes in iNOS activity, oxidative stress and melatonin levels in hypertensive patients treated with lacidipine. ( Acuña-Castroviejo, D; Escames, G; González, L; Khaldy, H; León, J, 2004) |
| "In a randomized double-blind study, 18 women, 47 to 63 years of age and with normal BP (N = 9) or treated essential hypertension (N = 9), received a 3-week course of a slow-release melatonin pill (3 mg) or placebo 1 h before going to bed." | 5.11 | Prolonged melatonin administration decreases nocturnal blood pressure in women. ( Arangino, S; Baldassari, F; Cagnacci, A; Cannoletta, M; Renzi, A; Volpe, A, 2005) |
| "To study effects of monotherapy with melatonin and combination melatonin + aceten on circadian pattern of hemodynamics in patients with essential hypertension stage II." | 5.09 | [Effects of melatonin alone and in combination with aceten on chronostructure of diurnal hemodynamic rhythms in patients with hypertension stage II]. ( Akhmetov, KZh; Komarov, FI; Shakirova, AN; Teĭblium, MM; Zaslavskaia, RM, 1999) |
| "The chronopharmacodynamics of angiotension-converting enzyme (ACE) inhibitors, such as ramipril (R), enalapril (E), acetene (A), caposide-50 (C-50) and the effect of the epiphyseal neurohormone melatonin used alone and in combination with cozaar (Co) and cintome (Ci) in the randomized groups including 124 patients with arterial hypertension (AH)." | 5.09 | [Time-dependent effects of antihypertensive agents and chronocorrecting action of melatonin in patients with arterial hypertension]. ( Biiasilov, N; Komarov, FI; Makarova, LA; Narmanova, OZh; Shakirova, AN; Zaslavskaia, RM, 2000) |
| "Monotherapy with caposide-50 (C-50) was compared to combined therapy C-50 + melatonin in 22 patients with essential hypertension stage II (mean age 60 years)." | 5.09 | [Capozide-50 alone and in combination with melatonin in therapy of hypertension]. ( Akhmetov, KZh; Biiasilov, NS; Teĭblium, MM; Zaslavskaia, RM, 2000) |
| " In this study the effect of ten weeks treatment with the beta-adrenoreceptor (beta-AR) blockers propranolol and ridazolol on melatonin synthesis and on sleep quality was examined in 42 patients suffering from essential hypertension." | 5.07 | Influence of chronic beta-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension. ( Demisch, L; Rommel, T, 1994) |
| " Among nonnutrient-nutraceuticals, soy isoflavones could be suggested in perimenopausal women, resveratrol in insulin-resistant patients, melatonin in study participants with night hypertension." | 5.05 | Nutraceuticals and blood pressure control: a European Society of Hypertension position document. ( Agabiti-Rosei, E; Borghi, C; Burnier, M; Cicero, AFG; Clement, D; Coca, A; Desideri, G; Grassi, G; Jelakovic, B; Kahan, T; Kreutz, R; Lovic, D; Lurbe, E; Mancia, G; Polonia, J; Redon, J; Tsioufis, K; Van De Borne, P, 2020) |
| "Here, we review the known relations between hypertension and obesity to inflammation and postulate the endogenous protective effect of melatonin and its potential as a therapeutic agent." | 4.98 | Anti-Inflammatory Effects of Melatonin in Obesity and Hypertension. ( Diez, ER; Ferder, L; Manucha, W; Prado, NJ, 2018) |
| "Melatonin secreted by the pineal gland plays an important role in the regulation of blood pressure (BP) and its administration reduces hypertension both in animals and humans." | 4.89 | Experimental models of melatonin-deficient hypertension. ( Paulis, L; Pechanova, O; Reiter, RJ; Simko, F, 2013) |
| "Add-on controlled-release melatonin to antihypertensive therapy is effective and safe in ameliorating nocturnal hypertension, whereas fast-release melatonin is ineffective." | 4.87 | Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. ( Grossman, E; Laudon, M; Zisapel, N, 2011) |
| "A test of the relative merits of timed melatonin for the treatment of cardiac ischemia as well as hypertension refractory to other drugs is documented against the background of earlier chronobiological studies on blood pressure (BP), disease risks, circadian hyper-amplitude-tension and melatonin effects broadly." | 4.82 | Melatonin, refractory hypertension, myocardial ischemia and other challenges in nightly blood pressure lowering. ( Bakken, EE; Cornélissen, G; Dilmagambetova, GS; Halberg, F; Ikonomov, O; Lilitsa, GV; Otsuka, K; Perfetto, F; Schwartzkopff, O; Singh, RB; Stoynev, A; Tarquini, R; Zaslavskaya, RM, 2004) |
| "Mouse myocardial microvascular endothelial cells were intervened with angiotensin II to establish hypertensive cell model and divided into control, hypertension (HP), hypertension + adenovirus negative control (HP + Ad-NC), hypertension + adenovirus carrying Mst1 (HP + Ad-Mst1), hypertension + melatonin (HP + MT), hypertension + adenovirus negative control + melatonin (HP + Ad-NC + MT), and hypertension + adenovirus carrying Mst1 + melatonin (HP + Ad-Mst1 + MT) groups." | 4.31 | Protective effects of melatonin on myocardial microvascular endothelial cell injury under hypertensive state by regulating Mst1. ( Han, R; Liu, Y; Luo, J; Wang, L; Wang, W; Wu, B, 2023) |
| "Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)." | 4.21 | ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022) |
| "In a previous study, we demonstrated that melatonin prevents kidney damage in a salt-induced hypertension model by decreasing oxidative stress." | 4.02 | Melatonin Prevents T Lymphocyte Infiltration to the Kidneys of Hypertensive Rats, Induced by a High-Salt Diet, by Preventing the Expression of CXCR3 Ligand Chemokines. ( Bier, A; Grossman, E; Khashab, R; Leibowitz, A; Sharabi, Y, 2021) |
| "The aim: Of the study was to investigate the effect of melatonin on the serum levels of ghrelin in patients with hypertension combined with osteoarthritis in order to identify them as informative and reliable markers of early diagnosis of progression of these comorbid diseases." | 4.02 | MELATONIN AND GRHELIN AS "EARLY" PROGNOSIS MARKERS OF PROGRESSION OF ARTERIAL HYPERTENSION AND OSTEOARTHRITIS IN THE CASE OF THEIR COMORBIDITY. ( Ilashchuk, TO; Navchuk, IV; Sobko, DI, 2021) |
| "The objective was to investigate the effects of melatonin and exercise on insulin resistance (IR), hypertension and fatigue syndrome in a rat model of type 2 diabetes mellitus (T2DM)." | 3.85 | Melatonin supplementation plus exercise behavior ameliorate insulin resistance, hypertension and fatigue in a rat model of type 2 diabetes mellitus. ( Go, HK; Kim, DH; Kim, MJ; Kwon, HS; Oak, MH; Rahman, MM, 2017) |
| "Hypertension can originate from early-life insults, whereas maternal melatonin therapy can be protective in a variety of models of programmed hypertension." | 3.85 | Maternal melatonin or agomelatine therapy prevents programmed hypertension in male offspring of mother exposed to continuous light. ( Chan, JYH; Hsu, CN; Lee, CT; Lin, YJ; Tain, YL, 2017) |
| "Our results indicated that antioxidant therapy, by melatonin or N-acetylcysteine, in pregnant rats with nitric oxide deficiency can prevent programmed hypertension in male adult offspring." | 3.83 | Maternal melatonin or N-acetylcysteine therapy regulates hydrogen sulfide-generating pathway and renal transcriptome to prevent prenatal N ( Chan, JY; Hsu, CN; Lee, CT; Tain, YL, 2016) |
| " Melatonin therapy prevented L-NAME-exacerbated hypertension and nephrosclerosis in young SHRs." | 3.80 | Renoprotective effects of melatonin in young spontaneously hypertensive rats with L-NAME. ( Cheng, MC; Huang, LT; Tain, YL; Wu, TH, 2014) |
| "Exposure of rats to continuous light attenuates melatonin production and results in hypertension development." | 3.80 | Hypertension and cardiovascular remodelling in rats exposed to continuous light: protection by ACE-inhibition and melatonin. ( Adamcova, M; Celec, P; Gvozdjakova, A; Kamodyova, N; Krajcirovicova, K; Kucharska, J; Paulis, L; Pechanova, O; Repova Bednarova, K; Simko, F; Zorad, S, 2014) |
| "Chronic continuous light exposure leads to melatonin deficiency along with complex neurohumoral activation resulting in hypertension development in rats." | 3.79 | Effect of captopril and melatonin on fibrotic rebuilding of the aorta in 24 hour light-induced hypertension. ( Adamcová, M; Aziriová, S; Hrenák, J; Krajčírovičová, K; Paulis, L; Repová-Bednárová, K; Simko, F, 2013) |
| "Several pathological conditions, including hypertension, atherosclerosis, diabetes, ischemia/reperfusion injury and nicotine-induced vasculopathy, are associated with vascular endothelial dysfunction characterized by altered secretory output of endothelial cells." | 3.79 | Vascular endothelial cells and dysfunctions: role of melatonin. ( Castrezzati, S; Favero, G; Foglio, E; Lonati, C; Rezzani, R; Rodella, LF; Rossini, C, 2013) |
| "Although melatonin lowers blood pressure in spontaneously hypertensive rats (SHR), its effect following antenatal and postpartum supplementation on the subsequent development of hypertension in SHR pups remains unknown." | 3.77 | Effects of antenatal, postpartum and post-weaning melatonin supplementation on blood pressure and renal antioxidant enzyme activities in spontaneously hypertensive rats. ( Lee, SK; Singh, HJ; Sirajudeen, KN; Sundaram, A; Zakaria, R, 2011) |
| "The study included 2 groups of patients with arterial hypertension and coronary heart disease treated by traditional therapy or its combination with melatonin." | 3.77 | [Significance of correlation between weather factors and hemodynamic parameters in patients with arterial hypertension and coronary heart desease receiving traditional treatment and combined therapy with melatonin]. ( , 2011) |
| "We examined the association between first morning urine melatonin levels and the risk of developing hypertension among 554 young women without baseline hypertension who were followed for 8 years." | 3.76 | Urinary melatonin and risk of incident hypertension among young women. ( Curhan, GC; Forman, JP; Schernhammer, ES, 2010) |
| " Melatonin diminishes myocardial fibrosis in rats exposed to continuous light and N-nitro-L-arginine-methyl ester (L-NAME) treatment and reduces production of endothelium-derived constricting factors in L-NAME-induced hypertension." | 3.76 | Remodelling of the heart and vessels in experimental hypertension: advances in protection. ( Pechanova, O; Simko, F, 2010) |
| "This work was aimed at study changes of the epiphyseal melatonin-producing function in elderly patients with hypertensive disease, as well as the relationships of those changes with the degree of arterial hypertension and 24-hour arterial pressure profile disorders." | 3.76 | [Pineal gland melatonin-producing function in elderly patients with hypertensive disease: age peculiarities]. ( Antoniuk-Shcheglova, IA; Bondarenko, EV; Shatilo, VB, 2010) |
| " Several groups have reported that melatonin produces a significant decrease in blood pressure in mammals and that pinealectomy in rats causes hypertension." | 3.75 | Melatonin reduces blood pressure in rats with stress-induced hypertension via GABAA receptors. ( Kang, YM; Li, HL; Xu, HY; Yu, L; Zhao, H, 2009) |
| "Oxidative stress and melatonin (the pineal hormone) are involved in the pathogenesis of aging and aging-related diseases, including essential arterial hypertension." | 3.74 | [Time dependent effect of melatonin administration on lipid peroxidation, superoxide dismutase activity and melatonin concentration in the elderly patients with essential arterial hypertension]. ( Czuczejko, J; Kedziora, J; Kedziora-Kornatowska, K; Kornatowski, T; Motyl, J; Pawluk, H; Szewczyk-Golec, K; van Marke de Lumen, K, 2008) |
| "The purpose of the study was to investigate effects of melatonin (MEL) on exploration and anxiety in normotensive Sprague-Dawley (SD) and hypertensive TGR(mREN2)27 (TGR) rats with high activity of renin-angiotensin system." | 3.74 | Effect of melatonin on exploration and anxiety in normotensive and hypertensive rats with high activity of renin-angiotensin system. ( Krsková, L; Vrabcová, M; Zeman, M, 2007) |
| "The features specific to the elderly nocturia group are as follows: (1) a decrease of the nighttime plasma melatonin level, (2) an increase of nighttime plasma catecholamine levels, (3) an increase of daytime and nighttime plasma natriuretic peptide levels, (4) an increase of blood pressure, (5) a decrease of daytime and nighttime urinary osmotic pressure, (6) an increase of total urine volume, and (7) an increase of the edema ratio before sleeping." | 3.74 | Biochemical and body composition analysis of nocturia in the elderly. ( Miyazato, M; Nishijima, S; Oda, M; Ogawa, Y; Owan, T; Sugaya, K, 2008) |
| "Melatonin secretion decreased in fructose fed rats that developed hypertension." | 3.74 | The role of melatonin in the pathogenesis of hypertension in rats with metabolic syndrome. ( Grossman, E; Leibowitz, A; Peleg, E; Shabtai, Z; Shamiss, A; Sharabi, Y, 2008) |
| "What is the effect of melatonin on jet lag syndrome? Jet lag desynchronizes the internal sleep-wakefulness cycle with the environmental light/dark cycle." | 3.72 | Melatonin and jet lag syndrome: experimental model and clinical implications. ( Oxenkrug, GF; Requintina, PJ, 2003) |
| "Our long-term goal is to determine the utility of melatonin in prevention of hypertension in type 1 diabetes." | 3.72 | Blood pressure-lowering effect of melatonin in type 1 diabetes. ( Bean, JA; Cavallo, A; Daniels, SR; Dolan, LM; Khoury, JC, 2004) |
| "We assessed the correlation between the rhythm of melatonin concentration and circadian blood pressure patterns in normal and hypertensive pregnancy." | 3.72 | Circadian melatonin concentration rhythm is lost in pregnant women with altered blood pressure rhythm. ( Garbati, E; Giannubilo, SR; Tranquilli, AL; Turi, A, 2004) |
| "To study mechanisms of action of natural magnetic field of the Earth on arterial pressure (AP) and melatonin production in patients with essential hypertension (EH) stage II." | 3.71 | [Melatonin production in hypertonic patients during magnetic storms]. ( Malinovskaia, NK; Oraevskiĭ, VN; Rapoport, SI; Shatalova, AM; Vetterberg, L, 2001) |
| "Early investigations have suggested a relationship between hypertension and melatonin, a pineal hormone." | 3.70 | Impaired basal sympathetic tone and alpha1-adrenergic responsiveness in association with the hypotensive effect of melatonin in spontaneously hypertensive rats. ( de Champlain, J; Foucart, S; K-Laflamme, A; Wu, L, 1998) |
| ") was compared to that of Cozaar combination with melatonin (3 mg before sleep) in 21 patients with hypertension stage II (mean age 62 years)." | 3.70 | [Comparative study of the effectiveness of Cozaar monotherapy and Cozaar and melatonin combined therapy in aged patients with hypertension]. ( Goncharov, LF; Goncharova, ZF; Komarov, FI; Makarova, LA; Zaslavskaia, RM, 1998) |
| "As melatonin has been found to play a role in the mechanisms of cardiovascular regulation, we designed the present study to evaluate whether the evening ingestion of the pineal hormone might interfere with the antihypertensive therapy in hypertensive patients well-controlled by nifedipine monotherapy." | 2.69 | Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. ( Fogari, R; Lusardi, P; Piazza, E, 2000) |
| " One group received moxonidine, 40 mg, alone in the morning, the other had moxonidine in the same dose in combination with melatonin, 3 mg, overnight." | 2.69 | [Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hypertension]. ( Akhmetov, KZh; Komarov, FI; Shakirova, AN; Teĭblium, MM; Zaslavskaia, RM, 2000) |
| "Melatonin is a physiological indoleamine secreted from the pineal gland into the bloodstream." | 2.61 | Effects of Melatonin Supplementation On Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Ghaedi, E; Ghavami, A; Hadi, A; Kafeshani, M; Moradi, S; Pourmasoumi, M, 2019) |
| "Melatonin plays a crucial role in major pathological processes associated with heart failure including ischemic injury, oxidative stress, apoptosis, and cardiac remodeling." | 2.58 | Melatonin in Heart Failure: A Promising Therapeutic Strategy? ( Maarman, GJ; Nduhirabandi, F, 2018) |
| "Hypertension affects target organs in different ways and cellular energy metabolism is frequently involved due to mitochondrial alterations that include a rise in reactive oxygen species production and an ATP synthesis decrease." | 2.55 | Melatonin, mitochondria and hypertension. ( Amaral, FG; Baltatu, OC; Campos, LA; Cipolla-Neto, J, 2017) |
| " The chronic administration of melatonin to individuals with hypertension induces a measurable drop in night time systolic and diastolic blood pressure." | 2.50 | [Anti-hypertensive action of melatoninergic compounds]. ( Inoue, Y, 2014) |
| "Melatonin is an endogenously produced indoleamine and secreted by the pineal gland." | 2.50 | Transcriptional regulation of programmed hypertension by melatonin: an epigenetic perspective. ( Chan, JY; Huang, LT; Tain, YL, 2014) |
| "Melatonin is a key endogenous hypotensive factor." | 2.50 | [Melatonin and arterial hypertension: from understanding pathogenesis to therapeutic modalities]. ( Pal'man, AD; Rapoport, SI, 2014) |
| " The recognition of the periodicity of biological processes makes the optimal dosing of certain drugs feasible." | 2.48 | [Physiological and pathophysiological role of the circadian clock system]. ( Halmos, T; Suba, I, 2012) |
| " The chronic administration of melatonin to individuals with hypertension induces a measurable drop in night time systolic and diastolic blood pressure." | 2.45 | The circadian melatonin rhythm and its modulation: possible impact on hypertension. ( Korkmaz, A; Reiter, RJ; Tan, DX, 2009) |
| "Melatonin has a role in blood pressure regulation." | 2.44 | Melatonin as a potential antihypertensive treatment. ( Paulis, L; Simko, F, 2007) |
| " We examined whether maternal melatonin therapy can prevent maternal high-fructose combined with post-weaning high-salt diet-induced programmed hypertension in adult offspring." | 1.48 | Maternal Melatonin Therapy Attenuated Maternal High-Fructose Combined with Post-Weaning High-Salt Diets-Induced Hypertension in Adult Male Rat Offspring. ( Chan, JYH; Lee, WC; Leu, S; Tain, YL; Wu, KLH, 2018) |
| "Treatment with melatonin eliminated the deleterious effect of HSD in the kidneys of Dahl salt-sensitive rats." | 1.43 | Melatonin prevents kidney injury in a high salt diet-induced hypertension model by decreasing oxidative stress. ( Barshack, I; Grossman, E; Leibowitz, A; Shemesh, C; Volkov, A; Voloshin, K, 2016) |
| "Melatonin was administered in drinking water (0." | 1.43 | Postnatal dexamethasone-induced programmed hypertension is related to the regulation of melatonin and its receptors. ( Chang, HY; Tain, YL, 2016) |
| "Treatment with melatonin facilitated normalization of arterial pressure and cerebral hemodynamics at night time." | 1.43 | [THE INFLUENCE OF MELATONIN ON THE PARAMETERS OF CEREBRAL HEMODYNAMICS IN PATIENTS WITH HYPERTENSIVE DISEASE]. ( Dem'yanenko, AV; Khoreva, ET; Voronin, TS, 2016) |
| " Chronic administration of L-NAME induced hypertension without a change in HR." | 1.43 | Effect of ivabradine, captopril and melatonin on the behaviour of rats in L-nitro-arginine methyl ester-induced hypertension. ( Adamcova, M; Aziriova, S; Baka, T; Hodosy, J; Krajcirovicova, K; Mojto, V; Paulis, L; Repova, K; Simko, F; Slavkovsky, P; Zorad, S, 2016) |
| "Melatonin was reported to prevent hypertension development." | 1.40 | Melatonin prevents maternal fructose intake-induced programmed hypertension in the offspring: roles of nitric oxide and arachidonic acid metabolites. ( Chan, JY; Lee, WC; Leu, S; Tain, YL; Wu, KL, 2014) |
| "Melatonin was administered in drinking water at the dose of 0." | 1.40 | Melatonin prevents neonatal dexamethasone induced programmed hypertension: histone deacetylase inhibition. ( Chien, SJ; Huang, LT; Kuo, HC; Lin, IC; Tain, YL; Wu, TH, 2014) |
| "Melatonin treatment significantly mitigated the increased expression of NADPH oxidase, pro-inflammatory mediators, and adhesion molecules." | 1.39 | Melatonin ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in rats with chronic intermittent hypoxia. ( Fung, ML; Hung, MW; Kravtsov, GM; Lau, CF; Poon, AM; Tipoe, GL, 2013) |
| "Chronic L-NAME treatment induced hypertension, elevated the oxidative load and inhibited NOS activity." | 1.36 | Melatonin interactions with blood pressure and vascular function during L-NAME-induced hypertension. ( Barta, A; Celec, P; Gardlik, R; Kunes, J; Paulis, L; Pechanova, O; Simko, F; Zicha, J, 2010) |
| "Melatonin-treated rats received 0." | 1.36 | Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats. ( Huang, LT; Lau, YT; Lin, CY; Lin, IC; Tain, YL, 2010) |
| "Melatonin plays a role in blood pressure (BP) control." | 1.35 | Effect of L-NAME-induced hypertension on melatonin receptors and melatonin levels in the pineal gland and the peripheral organs of rats. ( Benova, M; Herichova, I; Krajcirovicova, K; Paulis, L; Simko, F; Stebelova, K; Zeman, M, 2009) |
| "Melatonin treatment of IH-exposed animals decreased blood pressure, blood glucose, and ROS and nitrite/nitrate levels, and increased vasodilation and capillary perfusion." | 1.35 | Melatonin reduces microvascular damage and insulin resistance in hamsters due to chronic intermittent hypoxia. ( Bertuglia, S; Reiter, RJ, 2009) |
| "Melatonin has a capacity to improve disturbances in biological rhythms." | 1.35 | Effect of rhythmic melatonin administration on clock gene expression in the suprachiasmatic nucleus and the heart of hypertensive TGR(mRen2)27 rats. ( Herichová, I; Mravec, B; Stebelová, K; Szántóová, K; Zeman, M, 2009) |
| "Essential hypertension is a complex multifactorial disorder with epigenetic and environmental factors contributing to its prevalence." | 1.33 | Essential hypertension seems to result from melatonin-induced epigenetic modifications in area postrema. ( Irmak, MK; Sizlan, A, 2006) |
| "Reduction in the synthesis or bioavailability of nitric oxide plays a significant role in the development of myocardial infarction and hypertension." | 1.33 | Nitric oxide synthase inhibition in rats: melatonin reduces blood pressure and ischemia/reperfusion-induced infarct size. ( Aksulu, HE; Deniz, E; Sahna, E, 2006) |
| "Melatonin was administered as an antioxidant." | 1.32 | Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. ( Nava, M; Quiroz, Y; Rodriguez-Iturbe, B; Vaziri, N, 2003) |
| "Melatonin plays a role in the biologic regulation of circadian rhythms, including sleep." | 1.32 | Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. ( Garfinkel, D; Grossman, E; Jonas, M; Laudon, M; Zisapel, N, 2003) |
| "Melatonin treatment improved the maximal relaxation of mesenteric arteries to A23187 in SHR (P < 0." | 1.31 | Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats. ( Chulak, C; de Champlain, J; Girouard, H; Lamontagne, D; Lejossec, M, 2001) |
| "Melatonin receptors were not detectable in the anterior cerebral arteries of adult SHR." | 1.28 | Differential expression of melatonin receptors in spontaneously hypertensive rats. ( Laitinen, JT; Saavedra, JM; Viswanathan, M, 1992) |
| "Each subject's risk of developing breast cancer, cardiovascular diseases resulting from an elevated blood pressure, and emotional conditions was numerically evaluated according to epidemiologic questionnaires." | 1.27 | Circadian characteristics of urinary melatonin from clinically healthy young women at different civilization disease risks. ( Cornelissen, G; Halberg, E; Halberg, F; Haus, E; Kawasaki, T; Matsuoka, M; Omae, T; Ueno, M; Uezono, K; Wetterberg, L, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (4.62) | 18.7374 |
| 1990's | 11 (6.36) | 18.2507 |
| 2000's | 57 (32.95) | 29.6817 |
| 2010's | 82 (47.40) | 24.3611 |
| 2020's | 15 (8.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bier, A | 1 |
| Khashab, R | 1 |
| Sharabi, Y | 3 |
| Grossman, E | 7 |
| Leibowitz, A | 3 |
| Wu, D | 1 |
| Zhao, D | 2 |
| Huang, D | 2 |
| Sun, X | 1 |
| Li, KX | 1 |
| Feng, Y | 1 |
| Yan, QX | 1 |
| Li, XY | 1 |
| Cui, CP | 1 |
| Li, HD | 1 |
| Li, BY | 1 |
| Lee, EK | 1 |
| Poon, P | 1 |
| Yu, CP | 1 |
| Lee, VW | 1 |
| Chung, VC | 1 |
| Wong, SY | 1 |
| Balarastaghi, S | 1 |
| Barangi, S | 1 |
| Hosseinzadeh, H | 1 |
| Imenshahidi, M | 1 |
| Moosavi, Z | 1 |
| Razavi, BM | 1 |
| Karimi, G | 1 |
| Theofilis, P | 1 |
| Vordoni, A | 1 |
| Kalaitzidis, RG | 1 |
| Cvikova, D | 1 |
| Sutovska, H | 1 |
| Babarikova, K | 1 |
| Molcan, L | 1 |
| Franco, C | 3 |
| Sciatti, E | 3 |
| Favero, G | 4 |
| Bonomini, F | 4 |
| Vizzardi, E | 3 |
| Rezzani, R | 5 |
| Wang, L | 5 |
| Wang, W | 1 |
| Han, R | 1 |
| Liu, Y | 4 |
| Wu, B | 2 |
| Luo, J | 1 |
| Simko, F | 20 |
| Reiter, RJ | 8 |
| Paulis, L | 15 |
| Blagonravov, ML | 2 |
| Bryk, AA | 2 |
| Medvedeva, EV | 2 |
| Goryachev, VA | 2 |
| Chibisov, SM | 1 |
| Kurlaeva, AO | 1 |
| Agafonov, ED | 1 |
| Demurov, EA | 1 |
| Korshunova, AY | 1 |
| Borghi, C | 1 |
| Tsioufis, K | 1 |
| Agabiti-Rosei, E | 1 |
| Burnier, M | 1 |
| Cicero, AFG | 1 |
| Clement, D | 1 |
| Coca, A | 1 |
| Desideri, G | 1 |
| Grassi, G | 1 |
| Lovic, D | 1 |
| Lurbe, E | 1 |
| Kahan, T | 1 |
| Kreutz, R | 1 |
| Jelakovic, B | 1 |
| Polonia, J | 1 |
| Redon, J | 1 |
| Van De Borne, P | 1 |
| Mancia, G | 1 |
| Petrova, A | 1 |
| Kondratiuk, V | 1 |
| Karpenko, O | 1 |
| Ostashevska, T | 1 |
| Krasiuk, E | 1 |
| MacLean, MR | 1 |
| Nese, M | 1 |
| Riboli, G | 1 |
| Brighetti, G | 1 |
| Sassi, V | 1 |
| Camela, E | 1 |
| Caselli, G | 1 |
| Sassaroli, S | 1 |
| Borlimi, R | 1 |
| Aucoin, M | 1 |
| Cooley, K | 1 |
| Saunders, PR | 1 |
| Carè, J | 1 |
| Anheyer, D | 1 |
| Medina, DN | 1 |
| Cardozo, V | 1 |
| Remy, D | 1 |
| Hannan, N | 1 |
| Garber, A | 1 |
| Velayos, M | 1 |
| Muñoz-Serrano, AJ | 1 |
| Estefanía-Fernández, K | 1 |
| Sarmiento Caldas, MC | 1 |
| Moratilla Lapeña, L | 1 |
| López-Santamaría, M | 1 |
| López-Gutiérrez, JC | 1 |
| Li, J | 2 |
| Zhang, J | 1 |
| Shen, S | 1 |
| Zhang, B | 2 |
| Yu, WW | 1 |
| Toyoda, H | 1 |
| Huang, DQ | 1 |
| Le, MH | 1 |
| Nguyen, MH | 1 |
| Huang, R | 1 |
| Zhu, L | 1 |
| Wang, J | 7 |
| Xue, L | 1 |
| Liu, L | 2 |
| Yan, X | 2 |
| Huang, S | 1 |
| Li, Y | 6 |
| Xu, T | 1 |
| Li, C | 2 |
| Ji, F | 1 |
| Ming, F | 1 |
| Zhao, Y | 2 |
| Cheng, J | 1 |
| Wang, Y | 3 |
| Zhao, H | 2 |
| Hong, S | 1 |
| Chen, K | 2 |
| Zhao, XA | 1 |
| Zou, L | 1 |
| Sang, D | 1 |
| Shao, H | 1 |
| Guan, X | 1 |
| Chen, X | 2 |
| Chen, Y | 4 |
| Wei, J | 1 |
| Zhu, C | 1 |
| Wu, C | 1 |
| Moore, HB | 1 |
| Barrett, CD | 1 |
| Moore, EE | 1 |
| Jhunjhunwala, R | 1 |
| McIntyre, RC | 1 |
| Moore, PK | 1 |
| Hajizadeh, N | 1 |
| Talmor, DS | 1 |
| Sauaia, A | 1 |
| Yaffe, MB | 1 |
| Liu, C | 3 |
| Lin, Y | 1 |
| Dong, Y | 2 |
| Wu, Y | 2 |
| Bao, Y | 1 |
| Yan, H | 2 |
| Ma, J | 1 |
| Fernández-Cuadros, ME | 1 |
| Albaladejo-Florín, MJ | 1 |
| Álava-Rabasa, S | 1 |
| Usandizaga-Elio, I | 1 |
| Martinez-Quintanilla Jimenez, D | 1 |
| Peña-Lora, D | 1 |
| Neira-Borrajo, I | 1 |
| López-Muñoz, MJ | 1 |
| Rodríguez-de-Cía, J | 1 |
| Pérez-Moro, OS | 1 |
| Abdallah, M | 1 |
| Alsaleh, H | 1 |
| Baradwan, A | 1 |
| Alfawares, R | 1 |
| Alobaid, A | 1 |
| Rasheed, A | 1 |
| Soliman, I | 1 |
| Wendel Garcia, PD | 1 |
| Fumeaux, T | 1 |
| Guerci, P | 1 |
| Heuberger, DM | 1 |
| Montomoli, J | 2 |
| Roche-Campo, F | 1 |
| Schuepbach, RA | 1 |
| Hilty, MP | 1 |
| Poloni, TE | 1 |
| Carlos, AF | 1 |
| Cairati, M | 1 |
| Cutaia, C | 1 |
| Medici, V | 1 |
| Marelli, E | 1 |
| Ferrari, D | 1 |
| Galli, A | 1 |
| Bognetti, P | 1 |
| Davin, A | 1 |
| Cirrincione, A | 1 |
| Ceretti, A | 1 |
| Cereda, C | 1 |
| Ceroni, M | 1 |
| Tronconi, L | 1 |
| Vitali, S | 1 |
| Guaita, A | 1 |
| Leeds, JS | 1 |
| Raviprakash, V | 1 |
| Jacques, T | 1 |
| Scanlon, N | 1 |
| Cundall, J | 1 |
| Leeds, CM | 1 |
| Riva, A | 1 |
| Gray, EH | 1 |
| Azarian, S | 1 |
| Zamalloa, A | 1 |
| McPhail, MJW | 1 |
| Vincent, RP | 1 |
| Williams, R | 1 |
| Chokshi, S | 1 |
| Patel, VC | 1 |
| Edwards, LA | 1 |
| Alqarawi, W | 1 |
| Birnie, DH | 1 |
| Golian, M | 1 |
| Nair, GM | 1 |
| Nery, PB | 1 |
| Klein, A | 1 |
| Davis, DR | 1 |
| Sadek, MM | 1 |
| Neilipovitz, D | 1 |
| Johnson, CB | 1 |
| Green, MS | 1 |
| Redpath, C | 1 |
| Miller, DC | 1 |
| Beamer, P | 1 |
| Billheimer, D | 1 |
| Subbian, V | 1 |
| Sorooshian, A | 1 |
| Campbell, BS | 1 |
| Mosier, JM | 1 |
| Novaretti, JV | 1 |
| Astur, DC | 1 |
| Cavalcante, ELB | 1 |
| Kaleka, CC | 1 |
| Amaro, JT | 1 |
| Cohen, M | 1 |
| Huang, W | 1 |
| Li, T | 1 |
| Ling, Y | 1 |
| Qian, ZP | 1 |
| Zhang, YY | 1 |
| Xu, SB | 1 |
| Liu, XH | 1 |
| Xia, L | 1 |
| Yang, Y | 3 |
| Lu, SH | 1 |
| Lu, HZ | 1 |
| Zhang, R | 2 |
| Ma, JX | 1 |
| Tang, S | 1 |
| Li, CM | 1 |
| Wan, J | 1 |
| Wang, JF | 1 |
| Ma, JQ | 1 |
| Luo, JJ | 1 |
| Chen, HY | 2 |
| Mi, SL | 1 |
| Chen, SY | 1 |
| Su, YG | 1 |
| Ge, JB | 1 |
| Milheiro, SA | 1 |
| Gonçalves, J | 1 |
| Lopes, RMRM | 1 |
| Madureira, M | 1 |
| Lobo, L | 1 |
| Lopes, A | 1 |
| Nogueira, F | 1 |
| Fontinha, D | 1 |
| Prudêncio, M | 1 |
| M Piedade, MF | 1 |
| Pinto, SN | 1 |
| Florindo, PR | 1 |
| Moreira, R | 1 |
| Castillo-Lora, J | 1 |
| Delley, MF | 1 |
| Laga, SM | 1 |
| Mayer, JM | 1 |
| Sutjarit, N | 1 |
| Thongon, N | 1 |
| Weerachayaphorn, J | 1 |
| Piyachaturawat, P | 1 |
| Suksamrarn, A | 1 |
| Suksen, K | 1 |
| Papachristou, DJ | 1 |
| Blair, HC | 1 |
| Hu, Y | 1 |
| Shen, P | 1 |
| Zeng, N | 1 |
| Yan, D | 1 |
| Cui, L | 1 |
| Yang, K | 2 |
| Zhai, C | 1 |
| Yang, M | 1 |
| Lao, X | 1 |
| Sun, J | 1 |
| Ma, N | 1 |
| Wang, S | 1 |
| Ye, W | 1 |
| Guo, P | 1 |
| Rahimi, S | 1 |
| Singh, MP | 1 |
| Gupta, J | 1 |
| Nakanishi, I | 1 |
| Ohkubo, K | 1 |
| Shoji, Y | 1 |
| Fujitaka, Y | 1 |
| Shimoda, K | 1 |
| Matsumoto, KI | 1 |
| Fukuhara, K | 1 |
| Hamada, H | 1 |
| van der Boom, T | 1 |
| Gruppen, EG | 1 |
| Lefrandt, JD | 1 |
| Connelly, MA | 1 |
| Links, TP | 1 |
| Dullaart, RPF | 1 |
| Berry, JD | 1 |
| Bedlack, R | 1 |
| Mathews, D | 1 |
| Agnese, W | 1 |
| Apple, S | 1 |
| Meloncelli, S | 1 |
| Divizia, M | 1 |
| Germani, G | 1 |
| Adefegha, SA | 1 |
| Bottari, NB | 1 |
| Leal, DB | 1 |
| de Andrade, CM | 1 |
| Schetinger, MR | 1 |
| Martínez-Velasco, A | 1 |
| Perez-Ortiz, AC | 1 |
| Antonio-Aguirre, B | 1 |
| Martínez-Villaseñor, L | 1 |
| Lira-Romero, E | 1 |
| Palacio-Pastrana, C | 1 |
| Zenteno, JC | 1 |
| Ramirez, I | 1 |
| Zepeda-Palacio, C | 1 |
| Mendoza-Velásquez, C | 1 |
| Camacho-Ordóñez, A | 1 |
| Ortiz Bibriesca, DM | 1 |
| Estrada-Mena, FJ | 1 |
| Martin, BL | 1 |
| Thompson, LC | 1 |
| Kim, YH | 2 |
| Snow, SJ | 1 |
| Schladweiler, MC | 1 |
| Phillips, P | 1 |
| Harmon, M | 1 |
| King, C | 1 |
| Richards, J | 1 |
| George, I | 1 |
| Haykal-Coates, N | 1 |
| Gilmour, MI | 1 |
| Kodavanti, UP | 1 |
| Hazari, MS | 1 |
| Farraj, AK | 1 |
| Shen, Z | 1 |
| Zou, Y | 1 |
| Gao, K | 1 |
| Lazar, S | 1 |
| Wurtzel, JGT | 1 |
| Ma, P | 1 |
| Goldfinger, LE | 1 |
| Vukelic, M | 1 |
| Laloo, A | 1 |
| Kyttaris, VC | 1 |
| Chen, R | 1 |
| Chen, J | 2 |
| Xun, J | 1 |
| Hu, Z | 1 |
| Huang, Q | 2 |
| Steinhart, C | 1 |
| Shen, Y | 1 |
| Lu, H | 1 |
| Mansuri, A | 1 |
| Lokhande, K | 1 |
| Kore, S | 1 |
| Gaikwad, S | 1 |
| Nawani, N | 1 |
| Swamy, KV | 1 |
| Junnarkar, M | 1 |
| Pawar, S | 1 |
| Shaheen, MY | 1 |
| Basudan, AM | 1 |
| Niazy, AA | 1 |
| van den Beucken, JJJP | 1 |
| Jansen, JA | 1 |
| Alghamdi, HS | 1 |
| Gao, Q | 2 |
| Guo, X | 1 |
| Cao, Y | 1 |
| Jia, X | 1 |
| Xu, S | 1 |
| Lu, C | 2 |
| Zhu, H | 3 |
| Melku, M | 1 |
| Abebe, G | 1 |
| Teketel, A | 1 |
| Asrie, F | 1 |
| Yalew, A | 1 |
| Biadgo, B | 1 |
| Kassa, E | 1 |
| Damtie, D | 1 |
| Anlay, DZ | 1 |
| Ahmed, MFE | 1 |
| Ramadan, H | 1 |
| Seinige, D | 1 |
| Kehrenberg, C | 1 |
| Abd El-Wahab, A | 1 |
| Volkmann, N | 1 |
| Kemper, N | 1 |
| Schulz, J | 1 |
| Hu, MY | 1 |
| Wu, YN | 1 |
| McEvoy, MP | 1 |
| Wang, YF | 1 |
| Cong, WL | 1 |
| Liu, LP | 1 |
| Li, XX | 1 |
| Zhou, CL | 1 |
| Chen, WM | 1 |
| Wei, KL | 1 |
| Tung, SY | 1 |
| Shen, CH | 1 |
| Chang, TS | 1 |
| Yen, CW | 1 |
| Hsieh, YY | 1 |
| Chiu, WN | 1 |
| Hu, JH | 1 |
| Lu, SN | 1 |
| Hung, CH | 1 |
| Alakavuklar, MA | 1 |
| Fuqua, C | 1 |
| Luo, KL | 1 |
| Underwood, RS | 1 |
| Greenwald, I | 1 |
| Elashiry, MM | 1 |
| Elashiry, M | 1 |
| Zeitoun, R | 1 |
| Elsayed, R | 1 |
| Tian, F | 1 |
| Saber, SE | 1 |
| Elashry, SH | 1 |
| Tay, FR | 1 |
| Cutler, CW | 1 |
| O'Dowd, A | 1 |
| Maciel, M | 1 |
| Poole, ST | 1 |
| Jobling, MG | 1 |
| Rollenhagen, JE | 1 |
| Woods, CM | 1 |
| Sincock, SA | 1 |
| McVeigh, AL | 1 |
| Gregory, MJ | 1 |
| Maves, RC | 1 |
| Prouty, MG | 1 |
| Holmes, RK | 1 |
| Savarino, SJ | 1 |
| Mor, MK | 1 |
| Palevsky, PM | 1 |
| Kaufman, JS | 1 |
| Thiessen Philbrook, H | 1 |
| Weisbord, SD | 1 |
| Parikh, CR | 1 |
| John, CM | 1 |
| Phillips, NJ | 1 |
| Jarvis, GA | 1 |
| Zhu, Y | 1 |
| Kilburn, S | 1 |
| Kapoor, M | 1 |
| Chaturvedi, S | 1 |
| Shaw, KJ | 1 |
| Chaturvedi, V | 1 |
| Kong, X | 1 |
| Zhang, T | 1 |
| Xiao, H | 1 |
| Feng, X | 1 |
| Tu, H | 1 |
| Feng, J | 1 |
| Sabet, M | 1 |
| Tarazi, Z | 1 |
| Griffith, DC | 1 |
| Nguyen, F | 1 |
| Guan, P | 1 |
| Guerrero, DT | 1 |
| Kolla, V | 1 |
| Naraparaju, K | 1 |
| Perry, LM | 1 |
| Soberman, D | 1 |
| Pressly, BB | 1 |
| Alferiev, IS | 1 |
| Chorny, M | 1 |
| Brodeur, GM | 1 |
| Gao, X | 2 |
| Cheng, YH | 1 |
| Enten, GA | 1 |
| DeSantis, AJ | 1 |
| Gaponenko, V | 1 |
| Majetschak, M | 1 |
| Kim, DY | 1 |
| Choi, MJ | 1 |
| Ko, TK | 1 |
| Lee, NH | 1 |
| Kim, OH | 1 |
| Cheon, HG | 1 |
| Cai, H | 1 |
| Yip, V | 1 |
| Lee, MV | 1 |
| Wong, S | 1 |
| Saad, O | 1 |
| Ma, S | 1 |
| Ljumanovic, N | 1 |
| Khojasteh, SC | 1 |
| Kamath, AV | 1 |
| Shen, BQ | 1 |
| Cuypers, ML | 1 |
| Chanteux, H | 1 |
| Gillent, E | 1 |
| Bonnaillie, P | 1 |
| Saunders, K | 1 |
| Beckers, C | 1 |
| Delatour, C | 1 |
| Dell'Aiera, S | 1 |
| Ungell, AL | 1 |
| Nicolaï, J | 1 |
| Knapp, AK | 1 |
| Chen, A | 1 |
| Griffin-Nolan, RJ | 1 |
| Baur, LE | 1 |
| Carroll, CJW | 1 |
| Gray, JE | 1 |
| Hoffman, AM | 1 |
| Li, X | 4 |
| Post, AK | 1 |
| Slette, IJ | 1 |
| Collins, SL | 1 |
| Luo, Y | 1 |
| Smith, MD | 1 |
| Temitayo, GI | 1 |
| Olawande, B | 1 |
| Emmanuel, YO | 1 |
| Timothy, AT | 1 |
| Kehinde, O | 1 |
| Susan, LF | 1 |
| Ezra, L | 1 |
| Joseph, OO | 1 |
| Lev, S | 1 |
| Desmarini, D | 1 |
| Liuwantara, D | 1 |
| Sorrell, TC | 1 |
| Hawthorne, WJ | 1 |
| Djordjevic, JT | 1 |
| Verso, MG | 1 |
| Costantino, C | 1 |
| Marrella, A | 1 |
| Immordino, P | 1 |
| Vitale, F | 1 |
| Amodio, E | 1 |
| Wang, YD | 1 |
| Yao, WL | 1 |
| Xin, ZM | 1 |
| Han, TT | 1 |
| Wang, ZG | 1 |
| Chen, L | 1 |
| Cai, C | 1 |
| Zhang, Y | 5 |
| Ba, D | 1 |
| Wen, S | 1 |
| Tian, Q | 1 |
| Lv, W | 1 |
| Cheng, G | 1 |
| Li, N | 1 |
| Yue, XY | 1 |
| Chu, WJ | 1 |
| Chen, Q | 1 |
| Choi, ES | 1 |
| Zhao, X | 3 |
| Zhou, HD | 1 |
| Sun, XF | 1 |
| Sharma, S | 2 |
| Chhoker, S | 1 |
| Xie, C | 1 |
| Ong, EWY | 1 |
| Tan, ZK | 1 |
| Evans, S | 1 |
| Weinheimer, CJ | 1 |
| Kovacs, A | 1 |
| Williams, JW | 1 |
| Randolph, GJ | 1 |
| Jiang, W | 1 |
| Barger, PM | 1 |
| Mann, DL | 1 |
| Liu, J | 2 |
| Huang, Y | 1 |
| Kong, L | 1 |
| Yu, X | 1 |
| Feng, B | 1 |
| Liu, D | 1 |
| Zhao, B | 1 |
| Mendes, GC | 1 |
| Yuan, P | 1 |
| Ge, D | 1 |
| Wang, WM | 1 |
| Fontes, EPB | 1 |
| Li, P | 1 |
| Shan, L | 1 |
| He, P | 1 |
| Katoh, T | 1 |
| Sengoku, T | 1 |
| Hirata, K | 1 |
| Ogata, K | 1 |
| Suga, H | 1 |
| Shun, C | 1 |
| Yong-Yi, J | 1 |
| Mei-Li, C | 1 |
| Shi-Li, L | 1 |
| Jian-Bo, Z | 1 |
| Dan-Li, W | 1 |
| Zhi-Min, G | 1 |
| Ibrahim, AM | 1 |
| Zakhary, SY | 1 |
| Amin, SAW | 1 |
| Ugurlu, M | 1 |
| Fornari, VJ | 1 |
| Hartmann, MSM | 1 |
| Vanni, JR | 1 |
| Rodriguez, R | 1 |
| Langaro, MC | 1 |
| Pelepenko, LE | 1 |
| Zaia, AA | 1 |
| Nakanjako, D | 1 |
| Zalwango, F | 1 |
| Wairagala, P | 1 |
| Luboga, F | 1 |
| Andia Biraro, I | 1 |
| Bukirwa, VD | 1 |
| Mboowa, MG | 1 |
| Cose, S | 1 |
| Seeley, J | 1 |
| Elliott, A | 1 |
| Zhao, G | 1 |
| Sun, P | 1 |
| Hao, S | 1 |
| Wang, X | 2 |
| Qu, G | 1 |
| Xing, Y | 1 |
| Xu, X | 1 |
| Maierhofer, M | 1 |
| Rieger, V | 1 |
| Mayr, T | 1 |
| Zhang, Q | 1 |
| Bigliardi, AP | 1 |
| Fernandes, CLF | 1 |
| Pinto, EA | 1 |
| Dos Santos, M | 1 |
| Garcia, EM | 1 |
| Baisch, PRM | 1 |
| Soares, MCF | 1 |
| Muccillo-Baisch, AL | 1 |
| da Silva Júnior, FMR | 1 |
| Yu, W | 1 |
| Ju, C | 1 |
| Wang, K | 1 |
| Zheng, Z | 1 |
| Liu, H | 1 |
| Gao, Y | 1 |
| Martínez-Navarro, EM | 1 |
| Cebrián-Tarancón, C | 1 |
| Moratalla-López, N | 1 |
| Lorenzo, C | 1 |
| Alonso, GL | 1 |
| Salinas, RM | 1 |
| Bermúdez de Castro, JM | 1 |
| Modesto-Mata, M | 1 |
| Martín-Francés, L | 1 |
| García-Campos, C | 1 |
| Martínez de Pinillos, M | 1 |
| Martinón-Torres, M | 1 |
| Hasani, M | 1 |
| Wu, F | 2 |
| Warriner, K | 1 |
| Kurz, M | 1 |
| Gretzke, D | 1 |
| Hörlein, R | 1 |
| Turpault, S | 1 |
| Atzrodt, J | 1 |
| Derdau, V | 1 |
| Yao, Y | 1 |
| Ou, X | 1 |
| Zhao, S | 1 |
| Tian, B | 1 |
| Jin, S | 1 |
| Jiang, Z | 1 |
| Zhou, Z | 1 |
| Liu, M | 2 |
| Jiang, GD | 1 |
| Mou, LH | 1 |
| Chen, JJ | 1 |
| Li, ZY | 1 |
| He, SG | 1 |
| Reale, E | 1 |
| Fustinoni, S | 1 |
| Mercadante, R | 1 |
| Polledri, E | 1 |
| Hopf, NB | 1 |
| Grant, PC | 1 |
| Levy, K | 1 |
| Lattimer, TA | 1 |
| Depner, RM | 1 |
| Kerr, CW | 1 |
| Sato, J | 1 |
| Merenda, MEZ | 1 |
| Uemoto, AT | 1 |
| Dos Santos, MP | 1 |
| Barion, MRL | 1 |
| Carciofi, AC | 1 |
| de Paula Dorigam, JC | 1 |
| Ribeiro, LB | 1 |
| Vasconcellos, RS | 1 |
| Waller, SB | 1 |
| Peter, CM | 1 |
| Hoffmann, JF | 1 |
| Cleff, MB | 1 |
| Faria de, RO | 1 |
| Zani, JL | 1 |
| Martins, BA | 1 |
| Sande, D | 1 |
| Solares, MD | 1 |
| Takahashi, JA | 1 |
| Yang, S | 2 |
| Jia, Y | 1 |
| Yin, C | 1 |
| Zhao, R | 1 |
| Ojha, M | 1 |
| Deepa, M | 1 |
| Mo, J | 1 |
| Au, DW | 1 |
| Wan, MT | 1 |
| Shi, J | 1 |
| Zhang, G | 1 |
| Winkler, C | 1 |
| Kong, RY | 1 |
| Seemann, F | 1 |
| Bianco, M | 1 |
| Calvano, CD | 1 |
| Ventura, G | 1 |
| Bianco, G | 1 |
| Losito, I | 1 |
| Cataldi, TRI | 1 |
| Angiolella, L | 1 |
| Staudt, A | 1 |
| Duarte, PF | 1 |
| Amaral, BPD | 1 |
| Peixoto Andrade, BCO | 1 |
| Simas, NK | 1 |
| Correa Ramos Leal, I | 1 |
| Sangenito, LS | 1 |
| Santos, ALSD | 1 |
| de Oliveira, D | 1 |
| Junges, A | 1 |
| Cansian, RL | 1 |
| Paroul, N | 1 |
| Siu, J | 1 |
| Klingler, L | 1 |
| Hung, CT | 1 |
| Jeong, SH | 1 |
| Smith, S | 1 |
| Tingle, MD | 1 |
| Wagner Mackenzie, B | 1 |
| Biswas, K | 1 |
| Douglas, RG | 1 |
| Oza, AM | 1 |
| Lorusso, D | 1 |
| Aghajanian, C | 1 |
| Oaknin, A | 1 |
| Dean, A | 1 |
| Colombo, N | 1 |
| Weberpals, JI | 1 |
| Clamp, AR | 1 |
| Scambia, G | 1 |
| Leary, A | 1 |
| Holloway, RW | 1 |
| Gancedo, MA | 1 |
| Fong, PC | 1 |
| Goh, JC | 1 |
| O'Malley, DM | 1 |
| Armstrong, DK | 1 |
| Banerjee, S | 1 |
| García-Donas, J | 1 |
| Swisher, EM | 1 |
| Cella, D | 1 |
| Meunier, J | 1 |
| Goble, S | 1 |
| Cameron, T | 1 |
| Maloney, L | 1 |
| Mörk, AC | 1 |
| Bedel, J | 1 |
| Ledermann, JA | 1 |
| Coleman, RL | 1 |
| Vlek, SL | 1 |
| Burm, R | 1 |
| Govers, TM | 1 |
| Vleugels, MPH | 1 |
| Tuynman, JB | 1 |
| Mijatovic, V | 1 |
| Leicht, AS | 1 |
| Connor, J | 1 |
| Conduit, N | 1 |
| Vaquera, A | 1 |
| Gómez, MA | 1 |
| McKay, JA | 1 |
| Church, AL | 1 |
| Rubin, N | 1 |
| Emory, TH | 1 |
| Hoven, NF | 1 |
| Kuehn-Hajder, JE | 1 |
| Nelson, MT | 1 |
| Ramanna, S | 1 |
| Auerbach, EJ | 1 |
| Moeller, S | 1 |
| Bolan, PJ | 1 |
| Fox, NP | 1 |
| Leonard, M | 1 |
| Sjerps, MJ | 1 |
| Chang, EF | 1 |
| Hyun, S | 1 |
| Saejio, A | 1 |
| Shanmugam, S | 1 |
| Liu, X | 2 |
| Sun, M | 1 |
| Bai, Z | 1 |
| Jaque-Fernandez, F | 1 |
| Beaulant, A | 1 |
| Berthier, C | 1 |
| Monteiro, L | 1 |
| Allard, B | 1 |
| Casas, M | 1 |
| Rieusset, J | 1 |
| Jacquemond, V | 1 |
| Góngora-García, OR | 1 |
| Aca-Aca, G | 1 |
| Baz-Rodríguez, SA | 1 |
| Monte, A | 1 |
| Maganaris, C | 1 |
| Baltzopoulos, V | 1 |
| Zamparo, P | 1 |
| Wang, Z | 2 |
| Hou, Y | 1 |
| Cai, L | 1 |
| Tu, YJ | 1 |
| Tan, B | 1 |
| Jiang, L | 1 |
| Wu, ZH | 1 |
| Yu, HJ | 1 |
| Li, XQ | 1 |
| Yang, AD | 1 |
| Titze, IR | 1 |
| Palaparthi, A | 1 |
| Mau, T | 1 |
| González, MA | 1 |
| Goiri, F | 1 |
| Barandika, JF | 1 |
| García-Pérez, AL | 1 |
| Jatt, LP | 1 |
| Gandhi, MM | 1 |
| Guo, R | 1 |
| Sukhija-Cohen, A | 1 |
| Bhattacharya, D | 1 |
| Tseng, CH | 1 |
| Chew, KW | 1 |
| Onwumere, J | 1 |
| Pia Tek, J | 1 |
| Budnyak, T | 1 |
| Budnyk, S | 1 |
| Karim, Z | 1 |
| Thersleff, T | 1 |
| Kuśtrowski, P | 1 |
| Mathew, AP | 1 |
| Slabon, A | 1 |
| Guo, M | 1 |
| Zhao, T | 1 |
| Xing, Z | 1 |
| Qiu, Y | 2 |
| Pan, K | 1 |
| Li, Z | 2 |
| Zhou, W | 1 |
| Ghassemi Tabrizi, S | 1 |
| Arbuznikov, AV | 1 |
| Jiménez-Hoyos, CA | 1 |
| Kaupp, M | 1 |
| Lin, MH | 2 |
| Bulman, DM | 1 |
| Remucal, CK | 1 |
| Chaplin, BP | 1 |
| Laguerre, A | 1 |
| George, LA | 1 |
| Gall, ET | 1 |
| Emerson, MS | 1 |
| Wang, H | 4 |
| Maginn, EJ | 1 |
| Margulis, CJ | 1 |
| Li, H | 2 |
| Feng, W | 1 |
| Kang, X | 2 |
| Yan, S | 1 |
| Chao, M | 1 |
| Mo, S | 1 |
| Sun, W | 1 |
| Lu, Y | 1 |
| Chen, C | 2 |
| Stevens, DM | 1 |
| Adiseshaiah, P | 1 |
| Dasa, SSK | 1 |
| Potter, TM | 1 |
| Skoczen, SL | 1 |
| Snapp, KS | 1 |
| Cedrone, E | 1 |
| Patel, N | 1 |
| Busman-Sahay, K | 1 |
| Rosen, EP | 1 |
| Sykes, C | 1 |
| Cottrell, M | 1 |
| Dobrovolskaia, MA | 1 |
| Estes, JD | 1 |
| Kashuba, ADM | 1 |
| Stern, ST | 1 |
| Özütemiz, C | 1 |
| Neil, EC | 1 |
| Tanwar, M | 1 |
| Rubin, NT | 1 |
| Ozturk, K | 1 |
| Cayci, Z | 1 |
| Duscha, BD | 1 |
| Kraus, WE | 1 |
| Jones, WS | 1 |
| Robbins, JL | 1 |
| Piner, LW | 1 |
| Huffman, KM | 1 |
| Allen, JD | 1 |
| Annex, BH | 1 |
| Mehmood, T | 1 |
| Ahmad, I | 1 |
| Bibi, S | 1 |
| Mustafa, B | 1 |
| Ali, I | 1 |
| Dahal, RH | 1 |
| Chaudhary, DK | 1 |
| Kim, DU | 1 |
| Kim, J | 1 |
| Yeter, HH | 1 |
| Gonul, I | 1 |
| Guz, G | 1 |
| Helvaci, O | 1 |
| Korucu, B | 1 |
| Akcay, OF | 1 |
| Derici, U | 1 |
| Arinsoy, T | 1 |
| Neffati, R | 1 |
| Judeinstein, P | 1 |
| Rault, J | 1 |
| Xu, Y | 1 |
| Chai, X | 1 |
| Ren, T | 1 |
| Yu, S | 1 |
| Fu, Q | 2 |
| Ye, J | 1 |
| Ge, X | 1 |
| Song, J | 1 |
| Yang, H | 2 |
| El-Baba, TJ | 1 |
| Lutomski, CA | 1 |
| Kantsadi, AL | 1 |
| Malla, TR | 1 |
| John, T | 1 |
| Mikhailov, V | 1 |
| Bolla, JR | 1 |
| Schofield, CJ | 1 |
| Zitzmann, N | 1 |
| Vakonakis, I | 1 |
| Robinson, CV | 1 |
| Langham, MC | 1 |
| Caporale, AS | 1 |
| Wehrli, FW | 1 |
| Parry, S | 1 |
| Schwartz, N | 1 |
| den Boer, RB | 1 |
| Jones, KI | 1 |
| Ash, S | 1 |
| van Boxel, GI | 1 |
| Gillies, RS | 1 |
| O'Donnell, T | 1 |
| Ruurda, JP | 1 |
| Sgromo, B | 1 |
| Silva, MA | 1 |
| Maynard, ND | 1 |
| Sivieri, EM | 1 |
| Eichenwald, EC | 1 |
| Rub, D | 1 |
| Abbasi, S | 1 |
| Krahnert, I | 1 |
| Bolze, A | 1 |
| Gibon, Y | 1 |
| Fernie, AR | 1 |
| Huang, L | 1 |
| Wan, Y | 1 |
| Dang, Z | 1 |
| Yang, P | 1 |
| Yang, Q | 1 |
| Wu, S | 2 |
| Lin, CC | 1 |
| Hsu, CT | 1 |
| Liu, W | 2 |
| Huang, SC | 1 |
| Kortz, U | 1 |
| Mougharbel, AS | 1 |
| Chen, TY | 1 |
| Hu, CW | 1 |
| Lee, JF | 1 |
| Wang, CC | 1 |
| Liao, YF | 1 |
| Li, LJ | 1 |
| Li, L | 2 |
| Peng, S | 1 |
| Stimming, U | 1 |
| Hebbar Kannur, K | 1 |
| Yaqub, TB | 1 |
| Pupier, C | 1 |
| Héau, C | 1 |
| Cavaleiro, A | 1 |
| Yamamoto, S | 1 |
| Ono, A | 1 |
| Matsui, J | 1 |
| Hoshino, N | 1 |
| Akutagawa, T | 1 |
| Miyashita, T | 1 |
| Mitsuishi, M | 1 |
| Patel, SM | 1 |
| Smith, TG | 1 |
| Morton, M | 1 |
| Stiers, KM | 1 |
| Seravalli, J | 1 |
| Mayclin, SJ | 1 |
| Edwards, TE | 1 |
| Tanner, JJ | 1 |
| Becker, DF | 1 |
| Butcher, TW | 1 |
| Yang, JL | 1 |
| Hartwig, JF | 1 |
| Yu, MF | 1 |
| Xia, ZZ | 1 |
| Yao, JC | 1 |
| Feng, Z | 1 |
| Li, DH | 1 |
| Liu, T | 1 |
| Cheng, GJ | 1 |
| He, DL | 1 |
| Li, XH | 1 |
| Huurman, R | 1 |
| Schinkel, AFL | 1 |
| de Jong, PL | 1 |
| van Slegtenhorst, MA | 1 |
| Hirsch, A | 1 |
| Michels, M | 1 |
| Kataja, A | 1 |
| Tarvasmäki, T | 1 |
| Lassus, J | 1 |
| Sionis, A | 1 |
| Mebazaa, A | 1 |
| Pulkki, K | 1 |
| Banaszewski, M | 1 |
| Carubelli, V | 1 |
| Hongisto, M | 1 |
| Jankowska, E | 1 |
| Jurkko, R | 1 |
| Jäntti, T | 1 |
| Kasztura, M | 1 |
| Parissis, J | 1 |
| Sabell, T | 1 |
| Silva-Cardoso, J | 1 |
| Spinar, J | 1 |
| Tolppanen, H | 1 |
| Harjola, VP | 1 |
| Carsetti, A | 1 |
| Damiani, E | 1 |
| Casarotta, E | 1 |
| Scorcella, C | 1 |
| Domizi, R | 1 |
| Gasparri, F | 1 |
| Gabbanelli, V | 1 |
| Pantanetti, S | 1 |
| Carozza, R | 1 |
| Adrario, E | 1 |
| Donati, A | 1 |
| Almada, E | 1 |
| Pariani, A | 1 |
| Rivabella Maknis, T | 1 |
| Hidalgo, F | 1 |
| Vena, R | 1 |
| Favre, C | 1 |
| Larocca, MC | 1 |
| Lu, ZY | 1 |
| Jiang, WD | 1 |
| Wu, P | 1 |
| Kuang, SY | 1 |
| Tang, L | 1 |
| Yang, J | 1 |
| Zhou, XQ | 1 |
| Feng, L | 1 |
| Leal, M | 1 |
| Zampini, IC | 1 |
| Mercado, MI | 1 |
| Moreno, MA | 1 |
| Simirgiotis, MJ | 1 |
| Bórquez, J | 1 |
| Ponessa, G | 1 |
| Isla, MI | 1 |
| Saliu, IO | 1 |
| Amoo, ZA | 1 |
| Khan, MF | 1 |
| Olaleye, MT | 1 |
| Rema, V | 1 |
| Akinmoladun, AC | 1 |
| Khan, AU | 1 |
| Rahman, AU | 1 |
| Yuan, Q | 1 |
| Ahmad, A | 1 |
| Khan, ZUH | 1 |
| Mahnashi, MH | 1 |
| Alyami, BA | 1 |
| Alqahtani, YS | 1 |
| Ullah, S | 1 |
| Wirman, AP | 1 |
| Gao, M | 1 |
| Deng, L | 1 |
| Zhang, K | 1 |
| Wang, M | 1 |
| Xia, Z | 1 |
| Gao, D | 1 |
| Balkissou, AD | 1 |
| Poka-Mayap, V | 1 |
| Massongo, M | 1 |
| Djenabou, A | 1 |
| Endale-Mangamba, LM | 1 |
| Olomo, EJ | 1 |
| Boulleys-Nana, JR | 1 |
| Diffo-Sonkoue, L | 1 |
| Adidigue-Ndiome, R | 1 |
| Alexandra, AJE | 1 |
| Haman-Wabi, AB | 1 |
| Adama, S | 1 |
| Iddi-Faical, A | 1 |
| Pefura-Yone, EW | 1 |
| Zhao, Q | 1 |
| Tong, W | 1 |
| Ge, C | 1 |
| Norbäck, D | 1 |
| Li, B | 1 |
| Zhao, Z | 1 |
| Huang, C | 1 |
| Zhang, X | 1 |
| Qian, H | 1 |
| Yang, X | 1 |
| Sun, Y | 1 |
| Sundell, J | 1 |
| Deng, Q | 1 |
| Kim, HJ | 1 |
| Jeon, JW | 1 |
| Hwang, SM | 1 |
| Chu, KI | 1 |
| Cha, YH | 1 |
| Kwak, YD | 1 |
| Choi, SD | 1 |
| Aslam, M | 1 |
| Kim, CG | 1 |
| Zhou, J | 1 |
| Yang, E | 1 |
| Yang, W | 1 |
| Miller, MA | 1 |
| Cappuccio, FP | 1 |
| Sobko, DI | 1 |
| Ilashchuk, TO | 1 |
| Navchuk, IV | 1 |
| Nagasawa, Y | 1 |
| Nanami, M | 1 |
| Kuragano, T | 1 |
| Ishihara, M | 1 |
| Rahman, MM | 1 |
| Kwon, HS | 1 |
| Kim, MJ | 1 |
| Go, HK | 1 |
| Oak, MH | 1 |
| Kim, DH | 1 |
| Pechanova, O | 10 |
| Repova, K | 4 |
| Aziriova, S | 5 |
| Krajcirovicova, K | 7 |
| Celec, P | 4 |
| Tothova, L | 1 |
| Vrankova, S | 2 |
| Balazova, L | 1 |
| Zorad, S | 5 |
| Adamcova, M | 6 |
| Baltatu, OC | 1 |
| Amaral, FG | 1 |
| Campos, LA | 1 |
| Cipolla-Neto, J | 2 |
| Tain, YL | 11 |
| Lin, YJ | 1 |
| Chan, JYH | 2 |
| Lee, CT | 3 |
| Hsu, CN | 3 |
| Shao, G | 1 |
| Zhang, S | 1 |
| Nie, J | 1 |
| Tong, J | 1 |
| Baka, T | 5 |
| Poglitsch, M | 1 |
| Baker, J | 1 |
| Kimpinski, K | 1 |
| Leu, S | 2 |
| Lee, WC | 2 |
| Wu, KLH | 1 |
| Prado, NJ | 2 |
| Ferder, L | 1 |
| Manucha, W | 1 |
| Diez, ER | 2 |
| Pérez-Caraballo, AM | 1 |
| Ma, Y | 1 |
| Ockene, JK | 1 |
| Reeves, KW | 1 |
| Balasubramanian, R | 1 |
| Stanczyk, FZ | 1 |
| Allison, MA | 1 |
| Manson, JE | 1 |
| Sturgeon, SR | 1 |
| Obayashi, K | 5 |
| Saeki, K | 5 |
| Mullerova, M | 1 |
| Slavkovsky, P | 2 |
| Hodosy, J | 2 |
| Qiu, F | 1 |
| Xiao, D | 1 |
| Shi, L | 1 |
| Nduhirabandi, F | 1 |
| Maarman, GJ | 1 |
| Hadi, A | 1 |
| Ghaedi, E | 1 |
| Moradi, S | 1 |
| Pourmasoumi, M | 1 |
| Ghavami, A | 1 |
| Kafeshani, M | 1 |
| Rahbari-Oskoui, FF | 1 |
| Abramson, JL | 1 |
| Bruckman, AM | 1 |
| Chapman, AB | 1 |
| Cotsonis, GA | 1 |
| Johnson, SA | 1 |
| Bliwise, DL | 1 |
| Jeong, J | 1 |
| Harris, RA | 1 |
| Su, S | 1 |
| Tingen, MS | 1 |
| Kapuku, G | 1 |
| Pollock, JS | 1 |
| Pollock, DM | 1 |
| Harshfield, GA | 1 |
| Iwamoto, J | 2 |
| Okamoto, N | 1 |
| Tomioka, K | 1 |
| Nezu, S | 1 |
| Ikada, Y | 2 |
| Kurumatani, N | 4 |
| Renna, NF | 1 |
| Lembo, C | 1 |
| Ponce Zumino, AZ | 1 |
| Vazquez-Prieto, M | 1 |
| Miatello, RM | 1 |
| Hung, MW | 1 |
| Kravtsov, GM | 1 |
| Lau, CF | 1 |
| Poon, AM | 1 |
| Tipoe, GL | 1 |
| Fung, ML | 1 |
| Benova, T | 1 |
| Viczenczova, C | 3 |
| Radosinska, J | 1 |
| Bacova, B | 1 |
| Knezl, V | 1 |
| Dosenko, V | 1 |
| Weismann, P | 1 |
| Zeman, M | 6 |
| Navarova, J | 1 |
| Tribulova, N | 3 |
| Siew-Keah, L | 1 |
| Sundaram, A | 2 |
| Sirajudeen, KN | 2 |
| Zakaria, R | 2 |
| Singh, HJ | 2 |
| Cheng, MC | 1 |
| Wu, TH | 2 |
| Huang, LT | 6 |
| Repová-Bednárová, K | 1 |
| Hrenák, J | 1 |
| Chen, CC | 1 |
| Sheen, JM | 1 |
| Yu, HR | 1 |
| Tiao, MM | 1 |
| Kuo, HC | 2 |
| Dominguez-Rodriguez, A | 1 |
| Abreu-Gonzalez, P | 1 |
| Tone, N | 1 |
| Wu, KL | 1 |
| Chan, JY | 3 |
| Lin, IC | 2 |
| Chien, SJ | 1 |
| Repova Bednarova, K | 1 |
| Kamodyova, N | 1 |
| Kucharska, J | 1 |
| Gvozdjakova, A | 1 |
| Inoue, Y | 1 |
| Cicero, AF | 1 |
| Colletti, A | 1 |
| Pal'man, AD | 1 |
| Rapoport, SI | 6 |
| Rexhaj, E | 1 |
| Pireva, A | 1 |
| Paoloni-Giacobino, A | 1 |
| Allemann, Y | 1 |
| Cerny, D | 1 |
| Dessen, P | 1 |
| Sartori, C | 1 |
| Scherrer, U | 1 |
| Rimoldi, SF | 1 |
| Volkov, A | 1 |
| Voloshin, K | 1 |
| Shemesh, C | 1 |
| Barshack, I | 1 |
| Chang, HY | 1 |
| Khoreva, ET | 1 |
| Dem'yanenko, AV | 1 |
| Voronin, TS | 1 |
| Chaudagar, KK | 1 |
| Szeiffova Bacova, B | 2 |
| Egan Benova, T | 2 |
| Barancik, M | 2 |
| Diez, E | 1 |
| Klimentova, J | 1 |
| Cebova, M | 1 |
| Barta, A | 2 |
| Matuskova, Z | 1 |
| Rehakova, R | 1 |
| Kovacsova, M | 1 |
| Mojto, V | 1 |
| Ajibade, TO | 1 |
| Oyagbemi, AA | 1 |
| Durotoye, LA | 1 |
| Omóbòwálé, TO | 1 |
| Asenuga, ER | 1 |
| Olayemi, FO | 1 |
| Merkur'eva, GA | 1 |
| Ryzhak, GA | 1 |
| Xia, CM | 1 |
| Shao, CH | 1 |
| Xin, L | 1 |
| Wang, YR | 1 |
| Ding, CN | 1 |
| Shen, LL | 1 |
| Cao, YX | 1 |
| Zhu, DN | 1 |
| van Marke de Lumen, K | 2 |
| Kedziora-Kornatowska, K | 2 |
| Czuczejko, J | 2 |
| Szewczyk-Golec, K | 2 |
| Pawluk, H | 2 |
| Motyl, J | 1 |
| Kornatowski, T | 1 |
| Kedziora, J | 2 |
| Sahna, E | 3 |
| Deniz, E | 2 |
| Bay-Karabulut, A | 1 |
| Burma, O | 1 |
| Li, HL | 1 |
| Kang, YM | 1 |
| Yu, L | 1 |
| Xu, HY | 1 |
| Zaslavskaia, RM | 8 |
| Shcherban', EA | 2 |
| Logvinenko, SI | 3 |
| Cui, HW | 1 |
| Zhang, ZX | 1 |
| Gao, MT | 1 |
| Su, AH | 1 |
| Wang, MY | 1 |
| Petrák, J | 1 |
| Stebelová, K | 3 |
| Nagy, G | 1 |
| Krizanova, O | 1 |
| Herichová, I | 4 |
| Kvetnanský, R | 1 |
| Benova, M | 1 |
| Bertuglia, S | 1 |
| Szántóová, K | 1 |
| Mravec, B | 1 |
| Tan, DX | 2 |
| Korkmaz, A | 1 |
| Zamotaev, IuN | 2 |
| Enikeev, AKh | 1 |
| Kolomoets, NM | 1 |
| Zicha, J | 2 |
| Gardlik, R | 1 |
| Kunes, J | 2 |
| Forman, JP | 1 |
| Curhan, GC | 1 |
| Schernhammer, ES | 1 |
| Ferri, C | 1 |
| Grassi, D | 1 |
| Porteri, E | 1 |
| De Ciuceis, C | 1 |
| Rodella, LF | 2 |
| Paiardi, S | 1 |
| Boari, GE | 1 |
| Platto, C | 1 |
| Pilu, A | 1 |
| Avanzi, D | 1 |
| Rizzoni, D | 1 |
| Agabiti Rosei, E | 1 |
| Lilitsa, GV | 2 |
| Manchester, LC | 1 |
| Fuentes-Broto, L | 1 |
| Pozo, MJ | 1 |
| Gomez-Pinilla, PJ | 1 |
| Camello-Almaraz, C | 1 |
| Martin-Cano, FE | 1 |
| Pascua, P | 1 |
| Rol, MA | 1 |
| Acuña-Castroviejo, D | 2 |
| Camello, PJ | 1 |
| Lau, YT | 1 |
| Lin, CY | 1 |
| Dzherieva, IS | 1 |
| Volkova, NI | 1 |
| Peliciari-Garcia, RA | 1 |
| Zanquetta, MM | 1 |
| Andrade-Silva, J | 1 |
| Gomes, DA | 1 |
| Barreto-Chaves, ML | 1 |
| Lee, SK | 1 |
| Shatilo, VB | 2 |
| Bondarenko, EV | 2 |
| Antoniuk-Shcheglova, IA | 2 |
| Breus, TK | 2 |
| Laudon, M | 3 |
| Zisapel, N | 3 |
| Nagai, M | 1 |
| Kario, K | 1 |
| Halmos, T | 1 |
| Suba, I | 1 |
| Burgess, HJ | 1 |
| Scheer, FA | 3 |
| Morris, CJ | 1 |
| Garcia, JI | 1 |
| Smales, C | 1 |
| Kelly, EE | 1 |
| Marks, J | 1 |
| Malhotra, A | 1 |
| Shea, SA | 1 |
| Gonzalez Rodriguez, E | 1 |
| Hernandez, A | 1 |
| Dibner, C | 1 |
| Koehler Ballan, B | 1 |
| Pechère-Bertschi, A | 1 |
| Foglio, E | 1 |
| Rossini, C | 1 |
| Castrezzati, S | 1 |
| Lonati, C | 1 |
| İlhan, S | 1 |
| Ateşşahin, D | 1 |
| Ateşşahin, A | 1 |
| Mutlu, E | 1 |
| Onat, E | 1 |
| Pogan, L | 1 |
| Bissonnette, P | 1 |
| Parent, L | 1 |
| Sauvé, R | 1 |
| Nava, M | 1 |
| Quiroz, Y | 2 |
| Vaziri, N | 1 |
| Rodriguez-Iturbe, B | 2 |
| Girouard, H | 5 |
| Chulak, C | 3 |
| LeJossec, M | 2 |
| Lamontagne, D | 3 |
| de Champlain, J | 7 |
| Oxenkrug, GF | 1 |
| Requintina, PJ | 1 |
| Jonas, M | 1 |
| Garfinkel, D | 1 |
| Lemmer, B | 2 |
| Witte, K | 2 |
| Enzminger, H | 1 |
| Schiffer, S | 1 |
| Hauptfleisch, S | 1 |
| Chen, LG | 1 |
| Qu, Y | 1 |
| Xiao, J | 1 |
| Guo, HL | 1 |
| Wan, CM | 1 |
| Wang, ZR | 1 |
| Van Montfrans, GA | 1 |
| van Someren, EJ | 1 |
| Mairuhu, G | 1 |
| Buijs, RM | 2 |
| Cavallo, A | 1 |
| Daniels, SR | 1 |
| Dolan, LM | 1 |
| Bean, JA | 1 |
| Khoury, JC | 1 |
| Escames, G | 1 |
| Khaldy, H | 1 |
| León, J | 1 |
| González, L | 1 |
| Tranquilli, AL | 1 |
| Turi, A | 1 |
| Giannubilo, SR | 1 |
| Garbati, E | 1 |
| Denault, C | 1 |
| Ostrowska, Z | 1 |
| Kos-Kudła, B | 1 |
| Marek, B | 1 |
| Kajdaniuk, D | 1 |
| Wołkowska, K | 1 |
| Swietochowska, E | 1 |
| Górski, J | 1 |
| Szapska, B | 1 |
| Dulková, K | 1 |
| Bada, V | 1 |
| Zaslavskaya, RM | 1 |
| Dilmagambetova, GS | 1 |
| Halberg, F | 4 |
| Cornélissen, G | 3 |
| Otsuka, K | 2 |
| Singh, RB | 1 |
| Stoynev, A | 1 |
| Ikonomov, O | 1 |
| Tarquini, R | 1 |
| Perfetto, F | 1 |
| Schwartzkopff, O | 1 |
| Bakken, EE | 1 |
| Cagnacci, A | 1 |
| Cannoletta, M | 1 |
| Renzi, A | 1 |
| Baldassari, F | 1 |
| Arangino, S | 1 |
| Volpe, A | 1 |
| Irmak, MK | 1 |
| Sizlan, A | 1 |
| Aksulu, HE | 1 |
| Yalcin, R | 1 |
| Zengil, H | 1 |
| Peleg, E | 2 |
| Kamari, Y | 1 |
| Shen-Orr, Z | 1 |
| Rechciński, T | 1 |
| Kurpesa, M | 1 |
| Trzos, E | 1 |
| Krzeminska-Pakuła, M | 1 |
| Zenebe, W | 1 |
| Dobesová, Z | 1 |
| Kojsová, S | 1 |
| Jendeková, L | 1 |
| Sládková, M | 1 |
| Dovinová, I | 1 |
| Krsková, L | 1 |
| Vrabcová, M | 1 |
| Sugaya, K | 1 |
| Nishijima, S | 1 |
| Oda, M | 1 |
| Owan, T | 1 |
| Miyazato, M | 1 |
| Ogawa, Y | 1 |
| Smirnova, AV | 1 |
| Naumcheva, NN | 1 |
| Gaĭdash, SP | 1 |
| Shcherbakov, EA | 1 |
| Ferrebuz, A | 1 |
| Romero, F | 1 |
| Vaziri, ND | 1 |
| Shabtai, Z | 1 |
| Shamiss, A | 1 |
| Kozakiewicz, M | 1 |
| Bartosz, G | 1 |
| Milcu, I | 1 |
| Marcean, R | 1 |
| Ionescu, V | 1 |
| Kawashima, K | 2 |
| Nagakura, A | 1 |
| Wurzburger, RJ | 1 |
| Spector, S | 1 |
| Rommel, T | 1 |
| Demisch, L | 1 |
| Haus, E | 2 |
| Northrup, G | 1 |
| Portela, A | 1 |
| Wendt, H | 1 |
| Kumagai, Y | 1 |
| Watanabe, Y | 1 |
| Zaslavskaya, R | 1 |
| K-Laflamme, A | 1 |
| Wu, L | 2 |
| Foucart, S | 1 |
| Wang, R | 1 |
| Schnecko, A | 1 |
| van der Vliet, J | 1 |
| Scalbert, E | 1 |
| Delagrange, P | 1 |
| Guardiola-Lemaître, B | 1 |
| Komarov, FI | 4 |
| Goncharov, LF | 1 |
| Goncharova, ZF | 1 |
| Makarova, LA | 2 |
| Shakirova, AN | 3 |
| Teĭblium, MM | 3 |
| Akhmetov, KZh | 3 |
| Cabassi, A | 1 |
| Bouchard, JF | 1 |
| Dumont, EC | 1 |
| Le Jossec, M | 1 |
| Besner, JG | 1 |
| Lusardi, P | 1 |
| Piazza, E | 1 |
| Fogari, R | 1 |
| Shatalova, AM | 2 |
| Malinovskaia, NK | 2 |
| Vettenberg, L | 1 |
| Narmanova, OZh | 1 |
| Biiasilov, N | 1 |
| Biiasilov, NS | 1 |
| Oraevskiĭ, VN | 1 |
| Vetterberg, L | 1 |
| Kim, CY | 1 |
| Lee, BN | 1 |
| Kim, JS | 1 |
| He, W | 1 |
| Zhu, X | 1 |
| Qiu, X | 1 |
| Malaia, LT | 1 |
| Rachinskiĭ, ID | 2 |
| Shushliapin, OI | 1 |
| Viswanathan, M | 1 |
| Laitinen, JT | 1 |
| Saavedra, JM | 1 |
| Finocchiaro, LM | 1 |
| Scheucher, A | 1 |
| Alvarez, AL | 1 |
| Finkielman, S | 1 |
| Nahmod, VE | 1 |
| Pirola, CJ | 1 |
| Wetterberg, L | 3 |
| Sánchez de la Peña, S | 1 |
| Cowen, PJ | 1 |
| Bevan, JS | 1 |
| Gosden, B | 1 |
| Elliott, SA | 1 |
| Brismar, K | 1 |
| Hylander, B | 1 |
| Eliasson, K | 1 |
| Rössner, S | 1 |
| Miwa, Y | 1 |
| Fujimoto, K | 1 |
| Oohata, H | 1 |
| Nishino, H | 1 |
| Koike, H | 1 |
| Halberg, E | 1 |
| Kawasaki, T | 1 |
| Ueno, M | 1 |
| Uezono, K | 1 |
| Matsuoka, M | 1 |
| Omae, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Obstructive Sleep Apnea in Patients With Long COVID-19 Fatigue: a Multicentre Prospective Cohort Study[NCT05290350] | 300 participants (Anticipated) | Observational | 2022-03-10 | Recruiting | |||
| Melatonin Replacement Therapy Effects on Cardiac Autonomic Activity in Pinealectomized Patients[NCT03885258] | Early Phase 1 | 5 participants (Actual) | Interventional | 2017-05-02 | Completed | ||
| Association Between Plasma Melatonin and No-reflow[NCT03306303] | 1,700 participants (Actual) | Observational | 2014-01-01 | Completed | |||
| Melatonin and Essential Arterial Hypertension[NCT05257291] | Phase 2 | 23 participants (Actual) | Interventional | 2018-02-02 | Active, not recruiting | ||
| The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
| The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease[NCT03775096] | Phase 2 | 15 participants (Anticipated) | Interventional | 2019-04-04 | Recruiting | ||
| Melatonin Supplementation in Hypertensive Patients[NCT00238108] | Phase 2 | 16 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Identifying the Pathophysiology of Neurogenic Orthostatic Hypotension and the Effects of Melatonin on Reducing Supine Hypertension in Peripherally Intact Versus Denervated Post-ganglionic Sympathetic Nerves[NCT02963181] | Early Phase 1 | 10 participants (Actual) | Interventional | 2018-03-01 | Terminated (stopped due to PI leaving) | ||
| A Triple Blinded Randomized Controlled Trial of Oral Melatonin in Elevated Blood Pressure Individual (MRCTEBP)[NCT03764020] | Phase 3 | 320 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| Restoration of Sleep in Heart Failure Patients[NCT00869869] | Phase 2 | 0 participants (Actual) | Interventional | 2009-03-31 | Withdrawn (stopped due to No subjects were enrolled in this study. Funding ran out.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Systolic blood pressure as measured by 24-h ambulatory blood pressure monitoring (NCT00238108)
Timeframe: Measurement after 3 weeks of supplementation compared to baseline
| Intervention | mmHg (Mean) |
|---|---|
| Melatonin | -0.2 |
| Placebo | -0.4 |
Sleep efficiency as measured by polysomnography (total time asleep as a percentage of the 8-hour sleep opportunity) (NCT00238108)
Timeframe: Measurement after 3 weeks of supplementation
| Intervention | % (% asleep during 8 hour opportunity) (Mean) |
|---|---|
| Melatonin | 88.1 |
| Placebo | 80.5 |
35 reviews available for melatonin and Blood Pressure, High
| Article | Year |
|---|---|
Controlled-release oral melatonin supplementation for hypertension and nocturnal hypertension: A systematic review and meta-analysis.
Topics: Blood Pressure; Delayed-Action Preparations; Dietary Supplements; Humans; Hypertension; Melatonin; R | 2022 |
The Role of Melatonin in Chronic Kidney Disease and Its Associated Risk Factors: A New Tool in Our Arsenal?
Topics: Diabetes Mellitus, Type 2; Humans; Hypertension; Melatonin; Renal Insufficiency, Chronic; Renin-Angi | 2022 |
Hypotensive effects of melatonin in rats: Focus on the model, measurement, application, and main mechanisms.
Topics: Animals; Blood Pressure; Cardiovascular System; Humans; Hypertension; Hypotension; Melatonin; Mice; | 2022 |
Nutraceuticals and blood pressure control: a European Society of Hypertension position document.
Topics: Antihypertensive Agents; Antioxidants; Beverages; Blood Pressure; Dietary Supplements; Humans; Hyper | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
A systematic review of COVID-19 and obstructive sleep apnoea.
Topics: Comorbidity; Continuous Positive Airway Pressure; COVID-19; Diabetes Mellitus; Humans; Hypertension; | 2021 |
Melatonin, mitochondria and hypertension.
Topics: Animals; Antioxidants; Humans; Hypertension; Melatonin; Mitochondria | 2017 |
Role of melatonin in blood pressure regulation: An adjunct anti-hypertensive agent.
Topics: Animals; Antihypertensive Agents; Autonomic Nervous System; Blood Pressure; Cardiovascular System; H | 2018 |
Anti-Inflammatory Effects of Melatonin in Obesity and Hypertension.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Blood Pressure; Humans; Hypertension; Inflammation; | 2018 |
[Thermal and Lighting Housing Environments and Circadian Blood Pressure Variability: Findings from the HEIJO-KYO Cohort].
Topics: Aged; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Circadian Rhythm; Cohort Studies; Co | 2018 |
Melatonin in Heart Failure: A Promising Therapeutic Strategy?
Topics: Animals; Fibrosis; Heart Failure; Humans; Hypertension; Melatonin | 2018 |
Effects of Melatonin Supplementation On Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Melatonin; Randomized Controlled Tria | 2019 |
[Anti-hypertensive action of melatoninergic compounds].
Topics: Animals; Antihypertensive Agents; Biological Clocks; Blood Pressure; Circadian Rhythm; Humans; Hyper | 2014 |
Peripheral and central effects of melatonin on blood pressure regulation.
Topics: Blood Pressure; Central Nervous System; Humans; Hypertension; Melatonin; Reactive Oxygen Species; Re | 2014 |
Transcriptional regulation of programmed hypertension by melatonin: an epigenetic perspective.
Topics: Animals; Epigenesis, Genetic; Female; Gene Expression Regulation; Humans; Hypertension; Kidney; Mela | 2014 |
Nutraceuticals and Blood Pressure Control: Results from Clinical Trials and Meta-Analyses.
Topics: Amino Acids; Beta vulgaris; Blood Pressure; Carotenoids; Clinical Trials as Topic; Dietary Supplemen | 2015 |
[Melatonin and arterial hypertension: from understanding pathogenesis to therapeutic modalities].
Topics: Antihypertensive Agents; Circadian Rhythm; Humans; Hypertension; Melatonin; Sleep | 2014 |
Elevated heart rate and nondipping heart rate as potential targets for melatonin: a review.
Topics: Animals; Endothelium, Vascular; Heart Rate; Humans; Hypertension; Insulin Resistance; Melatonin; Pin | 2016 |
Protection of cardiac cell-to-cell coupling attenuate myocardial remodeling and proarrhythmia induced by hypertension.
Topics: Animals; Anti-Arrhythmia Agents; Antioxidants; Connexin 43; Fatty Acids, Omega-3; Gap Junctions; Hea | 2016 |
Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment.
Topics: Amides; Animals; Antihypertensive Agents; Chronotherapy; Circadian Rhythm; Fumarates; Humans; Hydrox | 2009 |
The circadian melatonin rhythm and its modulation: possible impact on hypertension.
Topics: Animals; Blood Pressure; Circadian Rhythm; Clinical Trials as Topic; Diastole; Humans; Hypertension; | 2009 |
Cardiac hypertrophy and remodelling: pathophysiological consequences and protective effects of melatonin.
Topics: Animals; Cardiomegaly; Hypertension; Melatonin; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2010 |
Melatonin, a potential therapeutic agent for smooth muscle-related pathological conditions and aging.
Topics: Aging; Animals; Antioxidants; Colon; Female; Humans; Hypertension; Melatonin; Mice; Muscle Contracti | 2010 |
[Arterial hypertension and metabolic disorders].
Topics: Circadian Rhythm; CLOCK Proteins; Depression; Humans; Hypertension; Hypertrophy, Left Ventricular; K | 2010 |
[Melatonin as a most important factor of natural electromagnetic fields impacting patients with hypertensive disease and coronary heart disease. Part 1].
Topics: Circadian Rhythm; Coronary Disease; Electromagnetic Fields; Humans; Hypertension; Melatonin | 2011 |
[Melatonin as a most important factor in the action of weak natural magnetic fields on patients with hypertensive disease and coronary heart disease. Part 2].
Topics: Animals; Atmospheric Pressure; Circadian Rhythm; Coronary Disease; Electromagnetic Fields; Humans; H | 2011 |
Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Delayed-Action Preparations; | 2011 |
[Sleep disorder and hypertension].
Topics: Circadian Rhythm; Habits; Humans; Hypertension; Melatonin; Sleep; Sleep Wake Disorders | 2012 |
[Physiological and pathophysiological role of the circadian clock system].
Topics: Aging; ARNTL Transcription Factors; Blood Coagulation Disorders; Cardiovascular Diseases; Circadian | 2012 |
[Arterial blood pressure circadian rhythm: significance and clinical implications].
Topics: Adrenergic Neurons; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Drug Chronotherapy; H | 2012 |
Experimental models of melatonin-deficient hypertension.
Topics: Animals; Blood Pressure; Circadian Rhythm; Darkness; Hypertension; Light; Melatonin; Pineal Gland; R | 2013 |
Melatonin, refractory hypertension, myocardial ischemia and other challenges in nightly blood pressure lowering.
Topics: Animals; Blood Pressure; Chronotherapy; Follow-Up Studies; Humans; Hypertension; Melatonin; Meta-Ana | 2004 |
Melatonin as a potential antihypertensive treatment.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Disease Models, Animal; Female; | 2007 |
Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind.
Topics: Animals; Antioxidants; Blood Pressure; Blood Vessels; Cardiotonic Agents; Humans; Hypertension; Mela | 2007 |
Clinical relevance of about-yearly changes in blood pressure and the environment.
Topics: Aldosterone; Blood Pressure; Chronobiology Phenomena; Humans; Hypertension; Melatonin; Models, Cardi | 1996 |
21 trials available for melatonin and Blood Pressure, High
| Article | Year |
|---|---|
Essential Hypertension and Oxidative Stress: Novel Future Perspectives.
Topics: Antioxidants; Cardiovascular Diseases; Essential Hypertension; Humans; Hypertension; Melatonin; Oxid | 2022 |
Essential Hypertension and Oxidative Stress: Novel Future Perspectives.
Topics: Antioxidants; Cardiovascular Diseases; Essential Hypertension; Humans; Hypertension; Melatonin; Oxid | 2022 |
Essential Hypertension and Oxidative Stress: Novel Future Perspectives.
Topics: Antioxidants; Cardiovascular Diseases; Essential Hypertension; Humans; Hypertension; Melatonin; Oxid | 2022 |
Essential Hypertension and Oxidative Stress: Novel Future Perspectives.
Topics: Antioxidants; Cardiovascular Diseases; Essential Hypertension; Humans; Hypertension; Melatonin; Oxid | 2022 |
Essential Hypertension and Oxidative Stress: Novel Future Perspectives.
Topics: Antioxidants; Cardiovascular Diseases; Essential Hypertension; Humans; Hypertension; Melatonin; Oxid | 2022 |
Essential Hypertension and Oxidative Stress: Novel Future Perspectives.
Topics: Antioxidants; Cardiovascular Diseases; Essential Hypertension; Humans; Hypertension; Melatonin; Oxid | 2022 |
Essential Hypertension and Oxidative Stress: Novel Future Perspectives.
Topics: Antioxidants; Cardiovascular Diseases; Essential Hypertension; Humans; Hypertension; Melatonin; Oxid | 2022 |
Essential Hypertension and Oxidative Stress: Novel Future Perspectives.
Topics: Antioxidants; Cardiovascular Diseases; Essential Hypertension; Humans; Hypertension; Melatonin; Oxid | 2022 |
Essential Hypertension and Oxidative Stress: Novel Future Perspectives.
Topics: Antioxidants; Cardiovascular Diseases; Essential Hypertension; Humans; Hypertension; Melatonin; Oxid | 2022 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
Nighttime administration of high-dose, sustained-release melatonin does not decrease nocturnal blood pressure in African-American patients: Results from a preliminary randomized, crossover trial.
Topics: Antihypertensive Agents; Black or African American; Blood Pressure; Blood Pressure Monitoring, Ambul | 2019 |
[Effect of the pineal gland peptide preparation on the diurnal profile of arterial pressure in middle-aged and elderly women with ischemic heart disease and arterial hypertension].
Topics: Aged; Aging; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Am | 2008 |
[Melatonin in combined therapy of patients with stable angina and arterial hypertension].
Topics: Adult; Aged; Angina Pectoris; Antioxidants; Blood Pressure; Blood Pressure Monitoring, Ambulatory; E | 2008 |
[Melatonin in the combined treatment of cardiovascular diseases].
Topics: Aged; Antihypertensive Agents; Antioxidants; Drug Therapy, Combination; Electrocardiography, Ambulat | 2010 |
[Metabolic disorders in elderly patients with hypertension and their correction with melatonin].
Topics: Aged; Antihypertensive Agents; Blood Glucose; Body Mass Index; Carbohydrate Metabolism; Drug Therapy | 2012 |
Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.
Topics: Actigraphy; Adrenergic beta-Antagonists; Double-Blind Method; Female; Humans; Hypertension; Male; Me | 2012 |
Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.
Topics: Actigraphy; Adrenergic beta-Antagonists; Double-Blind Method; Female; Humans; Hypertension; Male; Me | 2012 |
Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.
Topics: Actigraphy; Adrenergic beta-Antagonists; Double-Blind Method; Female; Humans; Hypertension; Male; Me | 2012 |
Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.
Topics: Actigraphy; Adrenergic beta-Antagonists; Double-Blind Method; Female; Humans; Hypertension; Male; Me | 2012 |
Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.
Topics: Actigraphy; Adrenergic beta-Antagonists; Double-Blind Method; Female; Humans; Hypertension; Male; Me | 2012 |
Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.
Topics: Actigraphy; Adrenergic beta-Antagonists; Double-Blind Method; Female; Humans; Hypertension; Male; Me | 2012 |
Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.
Topics: Actigraphy; Adrenergic beta-Antagonists; Double-Blind Method; Female; Humans; Hypertension; Male; Me | 2012 |
Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.
Topics: Actigraphy; Adrenergic beta-Antagonists; Double-Blind Method; Female; Humans; Hypertension; Male; Me | 2012 |
Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.
Topics: Actigraphy; Adrenergic beta-Antagonists; Double-Blind Method; Female; Humans; Hypertension; Male; Me | 2012 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2004 |
Changes in iNOS activity, oxidative stress and melatonin levels in hypertensive patients treated with lacidipine.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Cholesterol; Dihydropyridines; Female; Humans; Hype | 2004 |
Prolonged melatonin administration decreases nocturnal blood pressure in women.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Press | 2005 |
Prolonged melatonin administration decreases nocturnal blood pressure in women.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Press | 2005 |
Prolonged melatonin administration decreases nocturnal blood pressure in women.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Press | 2005 |
Prolonged melatonin administration decreases nocturnal blood pressure in women.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Press | 2005 |
Melatonin reduces night blood pressure in patients with nocturnal hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Circadian Rhythm; Delayed-Action Preparatio | 2006 |
Melatonin reduces night blood pressure in patients with nocturnal hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Circadian Rhythm; Delayed-Action Preparatio | 2006 |
Melatonin reduces night blood pressure in patients with nocturnal hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Circadian Rhythm; Delayed-Action Preparatio | 2006 |
Melatonin reduces night blood pressure in patients with nocturnal hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Circadian Rhythm; Delayed-Action Preparatio | 2006 |
[The influence of melatonin supplementation on circadian pattern of blood pressure in patients with coronary artery disease--preliminary report].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, | 2006 |
[Evaluation of different methods of treatment of patients with stable stenocardia combined with arterial hypertension according to echocardiographic data].
Topics: Adult; Aged; Angina Pectoris; Chronotherapy; Comorbidity; Drug Therapy, Combination; Echocardiograph | 2007 |
Influence of chronic beta-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension.
Topics: Adult; Depression, Chemical; Double-Blind Method; Female; Humans; Hypertension; Male; Melatonin; Mid | 1994 |
[Effects of melatonin alone and in combination with aceten on chronostructure of diurnal hemodynamic rhythms in patients with hypertension stage II].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Captopril; Circadian Rhythm; Drug Interactio | 1999 |
Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Double-Blind Method; Drug | 2000 |
[Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hypertension].
Topics: Antihypertensive Agents; Circadian Rhythm; Drug Therapy, Combination; Female; Hemodynamics; Humans; | 2000 |
[Time-dependent effects of antihypertensive agents and chronocorrecting action of melatonin in patients with arterial hypertension].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antioxidants; Blood Pressure; Blo | 2000 |
[Capozide-50 alone and in combination with melatonin in therapy of hypertension].
Topics: Antioxidants; Blood Pressure; Captopril; Circadian Rhythm; Drug Administration Schedule; Drug Combin | 2000 |
Melatonin secretion related to side-effects of beta-blockers from the central nervous system.
Topics: Adult; Atenolol; Circadian Rhythm; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertensi | 1988 |
118 other studies available for melatonin and Blood Pressure, High
| Article | Year |
|---|---|
Melatonin Prevents T Lymphocyte Infiltration to the Kidneys of Hypertensive Rats, Induced by a High-Salt Diet, by Preventing the Expression of CXCR3 Ligand Chemokines.
Topics: Animals; Cell Line; Chemokines; Hypertension; Kidney; Ligands; Male; Melatonin; Mesangial Cells; Rat | 2021 |
Estrogen-dependent depressor response of melatonin via baroreflex afferent function and intensification of PKC-mediated Na
Topics: Animals; Baroreflex; Blood Pressure; Estrogens; Female; Hypertension; Male; Melatonin; Pressorecepto | 2022 |
Melatonin improves arsenic-induced hypertension through the inactivation of the Sirt1/autophagy pathway in rat.
Topics: Animals; Apoptosis; Arsenic; Autophagy; Hypertension; Male; Melatonin; Oxidative Stress; Rats; Sirtu | 2022 |
Protective effects of melatonin on myocardial microvascular endothelial cell injury under hypertensive state by regulating Mst1.
Topics: Animals; Apoptosis; Beclin-1; Endothelial Cells; Heart Injuries; Hypertension; Melatonin; Mice; Mice | 2023 |
Melatonin as a rational alternative in the conservative treatment of resistant hypertension.
Topics: Animals; Blood Pressure; Brain; Conservative Treatment; Denervation; Hypertension; Hypertension, Ren | 2019 |
Structure of Rhythms of Blood Pressure, Heart Rate, Excretion of Electrolytes, and Secretion of Melatonin in Normotensive and Spontaneously Hypertensive Rats Maintained under Conditions of Prolonged Daylight Duration.
Topics: Animals; Blood Pressure; Circadian Rhythm; Electrolytes; Enzyme-Linked Immunosorbent Assay; Heart Ra | 2019 |
Bright Light Therapy Increases Blood Pressure and Changes the Structure of Circadian Rhythm of Melatonin Secretion in Spontaneously Hypertensive Rats.
Topics: Animals; Blood Pressure; Cardiovascular Physiological Phenomena; Circadian Rhythm; Hypertension; Mal | 2019 |
THE EFFECTIVENESS OF MELATONIN IN THE COMPLEX TREATMENT OF HYPERTENSION IN PATIENTS WITH STAGE 5 CHRONIC KIDNEY DISEASE.
Topics: Antihypertensive Agents; Antioxidants; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Centra | 2020 |
Melatonin: shining some light on pulmonary hypertension.
Topics: Endothelium; Humans; Hypertension; Hypertension, Pulmonary; Inflammasomes; Macrophages; Melatonin; P | 2020 |
MELATONIN AND GRHELIN AS "EARLY" PROGNOSIS MARKERS OF PROGRESSION OF ARTERIAL HYPERTENSION AND OSTEOARTHRITIS IN THE CASE OF THEIR COMORBIDITY.
Topics: Comorbidity; Humans; Hypertension; Melatonin; Osteoarthritis; Prognosis | 2021 |
Melatonin and gestational hypertension.
Topics: Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Melatonin; Pregnancy | 2021 |
Melatonin supplementation plus exercise behavior ameliorate insulin resistance, hypertension and fatigue in a rat model of type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Fatigue; Hypertension; I | 2017 |
Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril.
Topics: Acetylcysteine; Animals; Antihypertensive Agents; Captopril; Disease Models, Animal; Fibrosis; Heart | 2017 |
Maternal melatonin or agomelatine therapy prevents programmed hypertension in male offspring of mother exposed to continuous light.
Topics: Acetamides; Animals; Antioxidants; Female; Hypertension; Hypnotics and Sedatives; Light; Male; Mater | 2017 |
Effects of melatonin on mechanisms involved in hypertension using human umbilical vein endothelial cells.
Topics: Circadian Rhythm; Human Umbilical Vein Endothelial Cells; Humans; Hypertension; Melatonin; Vasoconst | 2017 |
Effect of Melatonin on the Renin-Angiotensin-Aldosterone System in l-NAME-Induced Hypertension.
Topics: Animals; Blood Pressure; Hypertension; Male; Melatonin; NG-Nitroarginine Methyl Ester; Rats; Rats, W | 2018 |
Maternal Melatonin Therapy Attenuated Maternal High-Fructose Combined with Post-Weaning High-Salt Diets-Induced Hypertension in Adult Male Rat Offspring.
Topics: Animals; Disease Models, Animal; Female; Fructose; Gene Expression Regulation; Hypertension; Male; M | 2018 |
Association of urinary levels of 6-sulfatoxymelatonin (aMT6s) with prevalent and incident hypertension.
Topics: Aged; Biomarkers; Blood Pressure; Case-Control Studies; Cross-Sectional Studies; Female; Humans; Hyp | 2018 |
Effect of melatonin on the behaviour of rats with continuous light-induced hypertension.
Topics: Animals; Behavior, Animal; Blood Pressure; Hypertension; Light; Male; Melatonin; Rats; Rats, Wistar | 2018 |
Aerobic exercise enhanced endothelium-dependent vasorelaxation in mesenteric arteries in spontaneously hypertensive rats: the role of melatonin.
Topics: Acetylcholine; Animals; Endothelium, Vascular; Hypertension; Male; Melatonin; Mesenteric Arteries; N | 2018 |
Ethnic Differences in Nighttime Melatonin and Nighttime Blood Pressure: A Study in European Americans and African Americans.
Topics: Adult; Biomarkers; Black or African American; Blood Pressure; Circadian Rhythm; Female; Georgia; Hea | 2019 |
Chronotherapy as a potential approach to hypertensive patients with elevated heart rate?
Topics: Antihypertensive Agents; Blood Pressure; Drug Chronotherapy; Heart Rate; Humans; Hypertension; Melat | 2019 |
Nocturnal urinary melatonin excretion is associated with non-dipper pattern in elderly hypertensives.
Topics: Actigraphy; Aged; Aged, 80 and over; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadia | 2013 |
Should melatonin be used to lower blood pressure?
Topics: Blood Pressure; Circadian Rhythm; Female; Humans; Hypertension; Male; Melatonin | 2013 |
Antifibrotic effect of melatonin--perspective protection in hypertensive heart disease.
Topics: Animals; Cardiomegaly; Fibrosis; Humans; Hypertension; Melatonin; Myocardium | 2013 |
Melatonin, given at the time of reperfusion, prevents ventricular arrhythmias in isolated hearts from fructose-fed rats and spontaneously hypertensive rats.
Topics: Animals; Antioxidants; Disease Models, Animal; Drug Evaluation, Preclinical; Fructose; Hypertension; | 2013 |
Melatonin ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in rats with chronic intermittent hypoxia.
Topics: Animals; Antioxidants; Aorta, Thoracic; Cell Adhesion Molecules; Chronic Disease; Endothelium, Vascu | 2013 |
Melatonin attenuates hypertension-related proarrhythmic myocardial maladaptation of connexin-43 and propensity of the heart to lethal arrhythmias.
Topics: Adaptation, Physiological; Animals; Arrhythmias, Cardiac; Blotting, Western; Cardiotonic Agents; Con | 2013 |
Effect of melatonin supplementation and cross-fostering on renal glutathione system and development of hypertension in spontaneously hypertensive rats.
Topics: Animals; Antioxidants; Blood Pressure; Dietary Supplements; Drug Evaluation, Preclinical; Female; Gl | 2014 |
Renoprotective effects of melatonin in young spontaneously hypertensive rats with L-NAME.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Amidohydrolases; Animals; Antioxidants; Arginine; Blood Pressure; Deoxy | 2014 |
Effect of captopril and melatonin on fibrotic rebuilding of the aorta in 24 hour light-induced hypertension.
Topics: Animals; Antifibrinolytic Agents; Antihypertensive Agents; Aorta; Captopril; Fibrillar Collagens; Hy | 2013 |
Association between light exposure at night and nighttime blood pressure in the elderly independent of nocturnal urinary melatonin excretion.
Topics: Actigraphy; Age Factors; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhyt | 2014 |
Melatonin attenuates prenatal dexamethasone-induced blood pressure increase in a rat model.
Topics: Animals; Blotting, Western; Dexamethasone; Female; Histone Deacetylases; Hypertension; Maternal Expo | 2014 |
The potential usefulness of serum melatonin level to predict heart failure in patients with hypertensive cardiomyopathy.
Topics: Cardiomyopathies; Female; Heart Failure; Humans; Hypertension; Male; Melatonin; Middle Aged; Predict | 2014 |
Relationship between melatonin secretion and nighttime blood pressure in elderly individuals with and without antihypertensive treatment: a cross-sectional study of the HEIJO-KYO cohort.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhyt | 2014 |
Melatonin therapy prevents programmed hypertension and nitric oxide deficiency in offspring exposed to maternal caloric restriction.
Topics: Animals; Arginine; Caloric Restriction; Female; Hypertension; In Vitro Techniques; Kidney; Male; Mel | 2014 |
Melatonin prevents maternal fructose intake-induced programmed hypertension in the offspring: roles of nitric oxide and arachidonic acid metabolites.
Topics: Animals; Arachidonic Acid; Blood Pressure; Chromatography, High Pressure Liquid; Electron Spin Reson | 2014 |
Melatonin prevents neonatal dexamethasone induced programmed hypertension: histone deacetylase inhibition.
Topics: Animals; Animals, Newborn; Blood Pressure; Body Weight; Dexamethasone; Gene Expression Regulation; H | 2014 |
Hypertension and cardiovascular remodelling in rats exposed to continuous light: protection by ACE-inhibition and melatonin.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Captopri | 2014 |
Asymmetric dimethylarginine attenuates the association of melatonin secretion with night-time blood pressure and dipping in elderly individuals.
Topics: Aged; Aged, 80 and over; Aging; Arginine; Blood Pressure; Body Mass Index; Circadian Rhythm; Cross-S | 2014 |
Prevention of vascular dysfunction and arterial hypertension in mice generated by assisted reproductive technologies by addition of melatonin to culture media.
Topics: Acetylcholine; Animals; Antioxidants; Blood Pressure; Culture Media; DNA Methylation; Embryo Culture | 2015 |
Melatonin prevents kidney injury in a high salt diet-induced hypertension model by decreasing oxidative stress.
Topics: Animals; Disease Models, Animal; Hypertension; Male; Melatonin; Oxidative Stress; Rats; Rats, Inbred | 2016 |
Postnatal dexamethasone-induced programmed hypertension is related to the regulation of melatonin and its receptors.
Topics: Animals; Blood Pressure; Dexamethasone; Female; Gene Expression Regulation; Heart; Hypertension; Kid | 2016 |
[THE INFLUENCE OF MELATONIN ON THE PARAMETERS OF CEREBRAL HEMODYNAMICS IN PATIENTS WITH HYPERTENSIVE DISEASE].
Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Central Nervous System Depressants; Cerebrova | 2016 |
Maternal melatonin or N-acetylcysteine therapy regulates hydrogen sulfide-generating pathway and renal transcriptome to prevent prenatal N
Topics: Acetylcysteine; Administration, Oral; Animals; Antioxidants; Biomarkers; Female; Fetal Development; | 2016 |
Modulation of systemic and aortic nitric oxide by melatonin and n-3 polyunsaturated fatty acids in isoproterenol affected spontaneously hypertensive and normotensive Wistar rats.
Topics: Animals; Antioxidants; Aorta; Dietary Supplements; Drug Evaluation, Preclinical; Fatty Acids, Omega- | 2016 |
Effect of melatonin on blood pressure and nitric oxide generation in rats with metabolic syndrome.
Topics: Animals; Blood Pressure; Brain; Enzyme Activation; Hypertension; Male; Melatonin; Metabolic Syndrome | 2016 |
Effect of ivabradine, captopril and melatonin on the behaviour of rats in L-nitro-arginine methyl ester-induced hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Behavior, Animal; Benzaz | 2016 |
Modulatory effects of melatonin and vitamin C on oxidative stress-mediated haemolytic anaemia and associated cardiovascular dysfunctions in rats.
Topics: Anemia, Hemolytic; Animals; Antioxidants; Ascorbic Acid; Blood Pressure; Catalase; Erythrocytes; Glu | 2017 |
Effects of melatonin on blood pressure in stress-induced hypertension in rats.
Topics: Animals; Blood Pressure; Conditioning, Operant; Electric Stimulation; Hypertension; Hypothalamus, An | 2008 |
[Time dependent effect of melatonin administration on lipid peroxidation, superoxide dismutase activity and melatonin concentration in the elderly patients with essential arterial hypertension].
Topics: Aged; Drug Administration Schedule; Humans; Hypertension; Lipid Peroxidation; Melatonin; Sodium Chlo | 2008 |
Melatonin protects myocardium from ischemia-reperfusion injury in hypertensive rats: role of myeloperoxidase activity.
Topics: Animals; Blood Pressure; Enzyme Inhibitors; Glutathione; Hypertension; Lipid Peroxidation; Male; Mal | 2008 |
Melatonin reduces blood pressure in rats with stress-induced hypertension via GABAA receptors.
Topics: Animals; Antihypertensive Agents; Bicuculline; Blood Pressure; Cerebral Ventricles; Down-Regulation; | 2009 |
[Circadian rhythm of melatonin and blood pressure changes in patients with essential hypertension].
Topics: Adult; Aged; Blood Pressure; Case-Control Studies; Circadian Rhythm; Female; Humans; Hypertension; M | 2008 |
Endocrine rhythms and expression of selected genes in the brain, stellate ganglia, and adrenals of hypertensive TGR rats.
Topics: Adrenal Glands; Aldosterone; Animals; Blood Pressure; Brain; Circadian Rhythm; Corticosterone; Dopam | 2008 |
Effect of L-NAME-induced hypertension on melatonin receptors and melatonin levels in the pineal gland and the peripheral organs of rats.
Topics: Animals; Aorta; Blotting, Western; Circadian Rhythm; Enzyme Inhibitors; Hypertension; Kidney; Light; | 2009 |
Melatonin reduces microvascular damage and insulin resistance in hamsters due to chronic intermittent hypoxia.
Topics: Analysis of Variance; Animals; Blood Glucose; Cricetinae; Glucose Clamp Technique; Hemodynamics; Hyp | 2009 |
Recent trends in hypertension treatment: perspectives from animal studies.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Disease Models, Animal; Female; Hu | 2009 |
Effect of rhythmic melatonin administration on clock gene expression in the suprachiasmatic nucleus and the heart of hypertensive TGR(mRen2)27 rats.
Topics: Animals; Blood Pressure; Circadian Rhythm; CLOCK Proteins; Gene Expression Regulation; Hypertension; | 2009 |
[The use of melaxen in combined therapy of arterial hypertension in subjects occupied in assembly line production].
Topics: Acrylates; Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Central Nervous Sys | 2009 |
Melatonin interactions with blood pressure and vascular function during L-NAME-induced hypertension.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Blood Pressure; Cyclooxygenase 2; Endothelins; Hype | 2010 |
Urinary melatonin and risk of incident hypertension among young women.
Topics: Adult; Cohort Studies; Female; Humans; Hypertension; Melatonin; Proportional Hazards Models; Risk Fa | 2010 |
Antioxidants and beneficial microvascular effects: is this the remedy?
Topics: Animals; Antioxidants; Disease Models, Animal; Drug Therapy, Combination; Flavonoids; Humans; Hypert | 2010 |
Effects of melatonin and Pycnogenol on small artery structure and function in spontaneously hypertensive rats.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Biomarkers; Cyclooxygenase 2; Disease Models | 2010 |
Remodelling of the heart and vessels in experimental hypertension: advances in protection.
Topics: Animals; Blood Vessels; Heart; Homeostasis; Hypertension; Melatonin; NF-kappa B; Nitric Oxide Donors | 2010 |
Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats.
Topics: Analysis of Variance; Animals; Arginine; Blood Pressure; Blotting, Western; Body Weight; Citrulline; | 2010 |
Expression of circadian clock and melatonin receptors within cultured rat cardiomyocytes.
Topics: Animals; Cells, Cultured; Circadian Clocks; Circadian Rhythm; Gene Expression; Hypertension; Male; M | 2011 |
Effects of antenatal, postpartum and post-weaning melatonin supplementation on blood pressure and renal antioxidant enzyme activities in spontaneously hypertensive rats.
Topics: Animals; Antioxidants; Blood Pressure; Female; Glutathione Peroxidase; Glutathione Peroxidase GPX1; | 2011 |
[Pineal gland melatonin-producing function in elderly patients with hypertensive disease: age peculiarities].
Topics: Adult; Age Factors; Aged; Aging; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rh | 2010 |
[Significance of correlation between weather factors and hemodynamic parameters in patients with arterial hypertension and coronary heart desease receiving traditional treatment and combined therapy with melatonin].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease; Drug Therapy, Combination; F | 2011 |
[The use of melatonin for correction of sleep disturbances in assembly-line shift workers with arterial hypertension].
Topics: Acrylates; Adult; Antihypertensive Agents; Circadian Clocks; Female; Humans; Hypertension; Imidazole | 2012 |
Melatonin: an adjunctive treatment for cardiometabolic disease?
Topics: Adrenergic beta-Antagonists; Female; Humans; Hypertension; Male; Melatonin; Sleep Initiation and Mai | 2012 |
Vascular endothelial cells and dysfunctions: role of melatonin.
Topics: Atherosclerosis; Diabetes Mellitus; Endothelial Cells; Humans; Hypertension; Melatonin; Nicotine; Re | 2013 |
2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced hypertension: the beneficial effects of melatonin.
Topics: Acetylcholine; Animals; Antioxidants; Blood Pressure; Cardiotonic Agents; Glutathione; Hypertension; | 2015 |
The effects of melatonin on Ca(2+) homeostasis in endothelial cells.
Topics: Adenosine Triphosphate; Animals; Aorta; Binding Sites; Bradykinin; Calcium; Cattle; Cells, Cultured; | 2002 |
Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats.
Topics: Administration, Oral; Animals; Antioxidants; Blood Pressure; Body Weight; Disease Models, Animal; Dr | 2003 |
Chronic antioxidant treatment improves sympathetic functions and beta-adrenergic pathway in the spontaneously hypertensive rats.
Topics: Acetylcysteine; Adenylyl Cyclases; Adrenergic beta-Agonists; Animals; Antioxidants; Aorta; Binding S | 2003 |
Melatonin and jet lag syndrome: experimental model and clinical implications.
Topics: Animals; Circadian Rhythm; Humans; Hypertension; Jet Lag Syndrome; Melatonin; Rats; Rats, Inbred SHR | 2003 |
Impaired nocturnal melatonin secretion in non-dipper hypertensive patients.
Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Enzyme-Linked Immunos | 2003 |
Transgenic TGR(mREN2)27 rats as a model for disturbed circadian organization at the level of the brain, the heart, and the kidneys.
Topics: Aging; Animals; Animals, Genetically Modified; Blood Pressure; Body Temperature; Brain; Circadian Rh | 2003 |
[Encapsulation of atrial natriuretic peptide (ANP) cDNA transfection cells and ANP circadian expression].
Topics: Animals; Atrial Natriuretic Factor; Caproates; CHO Cells; Circadian Rhythm; Cricetinae; Drug Deliver | 2003 |
Inhibitory effect of melatonin on alpha1-adrenergic-induced vasoconstriction in mesenteric beds of spontaneously hypertensive rats.
Topics: Adrenergic alpha-Agonists; Animals; Antioxidants; Blood Pressure; Disease Models, Animal; Dose-Respo | 2004 |
Blood pressure-lowering effect of melatonin in type 1 diabetes.
Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 1; Female; Humans; Hype | 2004 |
Circadian melatonin concentration rhythm is lost in pregnant women with altered blood pressure rhythm.
Topics: Blood Pressure; Circadian Rhythm; Female; Gestational Age; Humans; Hypertension; Melatonin; Pre-Ecla | 2004 |
Treatment by n-acetylcysteine and melatonin increases cardiac baroreflex and improves antioxidant reserve.
Topics: Acetylcysteine; Animals; Antioxidants; Baroreflex; Blood Pressure; Catecholamines; Erythrocytes; Glu | 2004 |
[Circadian rhythm of melatonin in patients with hypertension].
Topics: Adult; Blood Pressure Monitoring, Ambulatory; Case-Control Studies; Circadian Rhythm; Female; Humans | 2004 |
Plasma melatonin concentrations in hypertensive patients with the dipping and non-dipping blood pressure profile.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhy | 2005 |
[On the role of melatonin in development of arterial hypertension in the elderly persons].
Topics: Aged; Circadian Rhythm; Disease Progression; Humans; Hypertension; Melatonin; Middle Aged | 2005 |
Potential use of melatonin as adjunct antihypertensive therapy.
Topics: Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Humans; Hypertension; Melatonin | 2005 |
Essential hypertension seems to result from melatonin-induced epigenetic modifications in area postrema.
Topics: Area Postrema; Blood Pressure; Epigenesis, Genetic; Feedback; Gene Expression Regulation; Humans; Hy | 2006 |
Nitric oxide synthase inhibition in rats: melatonin reduces blood pressure and ischemia/reperfusion-induced infarct size.
Topics: Animals; Antioxidants; Blood Pressure; Hypertension; Male; Melatonin; Models, Animal; Myocardial Inf | 2006 |
The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension.
Topics: Acetylcysteine; Alkadienes; Animals; Antioxidants; Blood Pressure; Blotting, Western; Free Radical S | 2007 |
Effect of melatonin on exploration and anxiety in normotensive and hypertensive rats with high activity of renin-angiotensin system.
Topics: Animals; Anxiety; Exploratory Behavior; Hypertension; Male; Maze Learning; Melatonin; Motor Activity | 2007 |
Biochemical and body composition analysis of nocturia in the elderly.
Topics: Adult; Age Factors; Aged; Biomarkers; Blood Pressure; Body Composition; Catecholamines; Circadian Rh | 2008 |
[The first experience in application of melatonin (melaxen) for prophylaxis of the effects of magnetic storms on patients with cardiovascular pathology].
Topics: Antioxidants; Cardiovascular Diseases; Electromagnetic Fields; Female; Humans; Hypertension; Male; M | 2007 |
Melatonin ameliorates oxidative stress, inflammation, proteinuria, and progression of renal damage in rats with renal mass reduction.
Topics: Actins; Animals; Blood Pressure; Cell Movement; Collagen Type IV; Creatinine; Disease Models, Animal | 2008 |
The role of melatonin in the pathogenesis of hypertension in rats with metabolic syndrome.
Topics: Animals; Blood Pressure; Body Weight; Dietary Sucrose; Dietary Supplements; Disease Models, Animal; | 2008 |
Antioxidative effects of melatonin administration in elderly primary essential hypertension patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Antioxidants; Catalase; Glutathione; Glutathione P | 2008 |
[Investigation of the action of melatonin on blood sugar].
Topics: Animals; Blood Glucose; Hypertension; Melatonin; Mice; Rabbits | 1967 |
Melatonin in serum and the pineal of spontaneously hypertensive rats.
Topics: Aging; Animals; Hypertension; Male; Melatonin; Pineal Gland; Radioimmunoassay; Rats; Rats, Inbred SH | 1984 |
Impaired basal sympathetic tone and alpha1-adrenergic responsiveness in association with the hypotensive effect of melatonin in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Catecholamines; Heart Rate; Hypertension; Male; Melatonin; Norepinephrine; | 1998 |
Enhanced inhibition by melatonin of alpha-adrenoceptor-induced aortic contraction and inositol phosphate production in vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Animals; Antioxidants; Aorta; Cyclic AMP; Hypertension; In Vitro Techniques; Inositol Phosphates; Ma | 1998 |
Effects of SCN lesions on circadian blood pressure rhythm in normotensive and transgenic hypertensive rats.
Topics: Animals; Animals, Genetically Modified; Blood Pressure; Circadian Rhythm; Darkness; Heart Rate; Hete | 1998 |
[Comparative study of the effectiveness of Cozaar monotherapy and Cozaar and melatonin combined therapy in aged patients with hypertension].
Topics: Aged; Antihypertensive Agents; Circadian Rhythm; Drug Evaluation; Drug Therapy, Combination; Female; | 1998 |
Effect of antioxidant treatments on nitrate tolerance development in normotensive and hypertensive rats.
Topics: Acetylcysteine; Animals; Antioxidants; Coronary Vessels; Drug Tolerance; Endothelium, Vascular; Hype | 2000 |
[Melatonin production in hypertensive patients].
Topics: Adult; Biomarkers; Blood Pressure; Circadian Rhythm; Humans; Hypertension; Melatonin; Prognosis; Sev | 2000 |
Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Body Weight; Calcimycin; Enz | 2001 |
[Melatonin production in hypertonic patients during magnetic storms].
Topics: Adult; Blood Pressure; Earth, Planet; Electromagnetic Fields; Humans; Hypertension; Male; Melatonin | 2001 |
Effects of maternal-melatonin treatment on open-field behaviors and hypertensive phenotype in spontaneously hypertensive rats' (SHR) offspring.
Topics: Animals; Behavior, Animal; Blood Pressure; Body Weight; Exploratory Behavior; Female; Hypertension; | 2002 |
[Effect of melatonin on mean blood pressure and heart rate in morphine withdrawal rats].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Heart Rate; Hypertension; Male; Melatonin; Morphin | 1998 |
[State of the neurohumoral regulatory system in circulatory insufficiency].
Topics: 17-Ketosteroids; Adult; Aged; Aldosterone; Angiotensinogen; Coronary Disease; Cortisone; Endopeptida | 1976 |
[Disordered melatonin metabolism in chronic circulatory insufficiency].
Topics: Aged; Arrhythmias, Cardiac; Cardiovascular Diseases; Chronic Disease; Coronary Disease; Humans; Hype | 1978 |
Differential expression of melatonin receptors in spontaneously hypertensive rats.
Topics: Age Factors; Animals; Arteries; Autoradiography; Binding, Competitive; Body Temperature Regulation; | 1992 |
Pineal hyperactivity in spontaneously hypertensive rats: muscarinic regulation of indole metabolism.
Topics: Animals; Electric Stimulation; Hypertension; Indoles; Male; Melatonin; Parasympathetic Nervous Syste | 1990 |
Circadian rhythm of melatonin release from pineal hypothalamus and pituitary in hypertensive rats.
Topics: Animals; Circadian Rhythm; Hypertension; Hypothalamus; Melatonin; Organ Specificity; Pineal Gland; P | 1990 |
Treatment with beta-adrenoceptor blockers reduces plasma melatonin concentration.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Diuretics; Female; Humans; Hypertension; Male | 1985 |
Antihypertensive action of melatonin in the spontaneously hypertensive rat.
Topics: Animals; Antihypertensive Agents; Heart Rate; Hypertension; Male; Melatonin; Rats; Rats, Inbred SHR; | 1987 |
Circadian characteristics of urinary melatonin from clinically healthy young women at different civilization disease risks.
Topics: Adolescent; Adult; Breast Neoplasms; Cardiovascular Diseases; Circadian Rhythm; Depression; Female; | 1986 |